{"/":{"title":"notes","content":"\n\nI used to call this a [memex](https://en.wikipedia.org/wiki/Memex), \nthen toyed with calling it a [zettelkasten](https://en.wikipedia.org/wiki/Zettelkasten).\n\nFinally landed on just \"notes.\"\n\nPith [ftw](https://winstonchurchill.org/publications/finest-hour/finest-hour-145/editors-essay-churchill-on-jargon/). \n\n\u003cbr\u003e\u003c/br\u003e\n\nMany thanks to [jzhao](https://jzhao.xyz/) for the tooling.\n","lastmodified":"2022-12-24T20:06:44.412611511Z","tags":null},"/.trash/5-FU":{"title":"","content":"","lastmodified":"2022-12-24T20:06:44.412611511Z","tags":null},"/.trash/HIV":{"title":"","content":"# HIV\n## Biology\n- ...\n\n## AIDS-defining illnesses\n- ...\n\n\n## Therapy\n- [[ART]]","lastmodified":"2022-12-24T20:06:44.412611511Z","tags":null},"/.trash/TAX324":{"title":"","content":"","lastmodified":"2022-12-24T20:06:44.412611511Z","tags":null},"/.trash/vermorkenWhereWhenUse2021":{"title":"","content":"","lastmodified":"2022-12-24T20:06:44.412611511Z","tags":null},"/notes/HPV+-OPSCC-incidence-over-time":{"title":"HPV+ OPSCC incidence over time","content":"\n\"...overall HPV prevalence in OPSCC is increasing significantly over time: \n\nfrom 40.5% before 2000, \nto 64.3% between 2000 and 2004, \nand 72.2% between 2005 and 2009\"\n\n[[reference/@vermorkenWhereWhenUse2021]]\n\nquestions, probably won't be answered for decades:\n- what will the dropoff in sexual activity over the past decade or so do to these numbers? (don't have a reference for this, heard a few times that teens are having less sex, also not sure if this translates into young adults)\n- ditto for the HPV vaccine\n\nquestions that probably have an answer:\n- what's the average lead time from contracting HPV to getting OPSCC?","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/Prophylactic-Antibiotics":{"title":"Prophylactic Antibiotics","content":"\n# Fluoroquinolones?\nLVQ classic in cancer patients, but some folks starting to use augmentin.\n\n@eileen_hasse\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/acute-lymphoblastic-leukemia":{"title":"{{Acute Lymphoblastic Leukemia}}","content":"\n# ALL\n2022-07-26 Kate Baker intro\n2022-08-03 Vivek Patel mgmt\n\n---\n\n##  overview of ALL\n\n- PB flow: MPO -ve, TDT+, look for CD19, CD20, CD22 (see tx below)\n- BMBx, excisional LN bx\n- cyto (e.g. if Ph+ may add TKI)\n- PCR: typically BCR-ABL p190, can also have p210, p230\n\t- order p190, p210\n\t- p190 typically acute (shorter)\n\t- p210 typically chronic\n- CNS eval and tx\n- JCO 2010 MD Anderson study on Ritux: used % positivity of CD20 (\u003e20%) as inclusion, in practice no % positivity is reported out\n\n- add targeted therapies based on findings\n\t- e.g. CD20+ -\u003e rituximab, Ph+ -\u003e TKI\n\t- my first ALL pt had Ph+, CD20+, so got R-HyperCVAD/MA+TKI\n\n## approach to therapy\n\n- CD19: blinutumomab, CAR-T\n- CD20: rituximab\n- CD22: inotuzumab ozogamicin\n- if age \u003c40: (R)HyperCVAD/MA(+TKI) -\u003e cure ~50% if able to tolerate tx, MRD -ve after first induction\n- blinutumomab, inotuzumab viewed as bridge to transplant, used in salvage\n- if targeted therapy available (e.g. dasatinib), typically add back targeted agent s/p SCT at D+101. \n\t- BiTE/CAR-T recommended against s/p SCT unless major relapse, as likelihood of clinically significant GVHD is worrisome.\n- Kantarjian, Lancet Onc 2018, pII MD Anderson: \u003e60, Ph-, hyper-mini-CVD + inotuzumab. Not a comparative study. In practice, inotuzumab has significant hepatotoxicity, etc,. so often skipped or used in a reduced fashion.","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/diary/2019-10-19":{"title":"","content":"I think I'm close to a comfortable place with Vimwiki.\nStill many enhancements to be made, but maybe not?\nE.g. I considered making a Vimwiki -\u003e Jekyll workflow,\nbut the more I think about it the more I'm convinced it's better to\nkeep these separate and migrate material as it makes sense\n(use the Vimwiki for a personal wiki,\nprivate Git repo,\nand when stuff is interesting enough to share then y/p the relevant parts).\n\nThis is my first diary entry, btw.\nSun 19 Jan 2020 09:20:54 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/diary/2019-11-13":{"title":"","content":"On my way back to PHX, this time for an interview at UofA.\n\nExcited to see fam,\nalso get the X220 going (writing this on the 2011 macbook).\n\nAs of now, top programs are:\n1. UPMC (pitt)\n2. URMC (rochester)\n3. VUMC (vandy - haven't yet interviewed, maybe will jump to 1 or 2)\n4. CCF (haven't yet interviewed, but will likely remain #4 or go down)\n5. UofA (interview 11-15)\n7. UofU (interview 11-something_after_15)\n\nLooking forward to finishing ASH poster, also readmission paper review.\nExcited to write bone marrow failure manuscript.\nReally enjoying this little NLP on Pycon vids project,\nfound the master repo with all the links to pretty much ever Pycon-esque vid ever,\nall on GitHub in JSON format.\nProbs a waste of time, but if I find anything cool it would be good to submit to Pycon\n(it's in Pittsburgh in 2020, but in April so Lori might just kill me...).\n\n\nSun 19 Jan 2020 09:20:54 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/diary/2020-01-19":{"title":"","content":"# Come follow me\n\n## 1 Nephi 8-10 - Lehi's vision\n\n### 8\n- How did Lehi get to the Tree? Wandering in darkness -\u003e *eleison* -\u003e large and spacious field -\u003e tree -\u003e go forth and partake. No rod here, and angel seems to have disappeared.\n\n- 8:27 \"manner of dress was exceedingly fine\": more on class differences, attitudes (mocking, shaming)\n\n- 8:37 \"did exhort them\": despite seeing the vision, Lehi did not think it was fatalistic? Laman \u0026 Lemuel redeemable?\n\n- 8: 24 \"clinging\" fell away, vs. 8:30 \"continually holding fast\" were able to not heed the great and spacious folks. Maybe a difference between the dead word and the living word? Sense of desperation in \"cling\" vs. self-sufficiency in \"holding fast.\" Also 8:24 came forth and partook, vs. 8:30 \"fell down\" and partook (cf. Lehi above and *eleison* prior to deliverance).\n\n- overall: major contrasts of humility and pride - *eleison* and \"fell down and partook\" vs. \"exceedingly fine dress,\" also perhaps superficial vs. deeper use of the \"rod\" (clinging vs. holding fast) - in what ways may these be one concept? Authenticity and phenomenological approach to faith rather than (ill)preconceived notions of what faith *should* be?\n\n### 9\n- 9:5 wise purpose \"which purpose I know not\"\n- 9:6 \"all\" used repeatedly\n\n### 10\n- 10:17 \"see, and hear, and know\"\n    - seems progressive: intellectual understanding/exposure to the idea, then hear as in \"hearken\", then sure knowledge from experience.\n    - \"hear\" etymology, fun tidbit: 'Old English also had the excellent adjective hiersum \"ready to hear, obedient,\" literally \"hear-some\" with suffix from handsome, etc.' https://www.etymonline.com/word/hear\n\nSun 19 Jan 2020 10:03:22 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/diary/diary":{"title":"","content":"# Diary\n\n## 2019\n\n### November\n\n    - [2019-11-13](2019-11-13.md)\n\n### October\n\n    - [2019-10-19](2019-10-19.md)\n\n\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/health/sleep":{"title":"","content":"# sleep\n\n## sleep in residency\n- Where are residents in terms of sleepiness?\n    - Residents have Epworth Sleepiness Scale ratings\nhigher on average than people with obstructive sleep apnea\nbut lower than people with narcolepsy.\n\n- Environmental factors unmask but do not cause sleepiness\n    - i.e. it's not the lecture that put you to sleep,\nyou were sleepy and the lecture gave you an opportunity to sleep\n\n- Sleep hygiene\n    - \"Practice gratitude at bed, not worries\"\n    - Pager and cell phone *off* when sleeping\n\n- Melatonin\n    - ideally, take 12h before desired waking time (take at 5pm if 5am wakeup is desired)\n\nTue 30 Jun 2020 10:09:21 AM CDT\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/identity/professional-identity":{"title":"","content":"# professional identity\n\n## awkward transitions\nMedical school, especially at the end, is awkward - you're giving orders, but can't really,\ncarrying patients, but not really, etc.\nYou can do a lot of good, but are purposefully (and thankfully) handicapped.\n\nTo what degree is residency similarly awkward?\nFull MD/DO, can write orders, but still heavily (thankfully) supervised.\n\n## motivation\nDaniel Pink's Drive: autonomy, mastery, purpose (these map to Cal Newport's[^cn3] autonomy, competence, connection)\n\n### autonomy\nSee \"awkward transitions\"\n\n### mastery\nCan't ever fully master medicine,\nas it's too large (even if scientific knowledge remained static),\nand scientific knowledge is exponentially expanding.\nThe joyfulness of infinite play lies in learning to start something we cannot finish.\nSee [Carse's _Finite and Infinite Games_](finite_infinite_games_james_p_carse.md).\n\n### purpose\nWork-life integration, rather than balance.\nRegain purpose with self-care,\nmeaningful problems,\nsurround yourself with great colleagues.\n\n\n\n[^cn3]: he didn't make these up, of course, and both Pink and Newport are popularizing large and deep academic fields\nTue 30 Jun 2020 10:55:14 AM CDT\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2020-07-02-noon-conference":{"title":"","content":"# Case 1: New, acute onset ascites and abdominal pain\n\nPortal vein thrombosis often does *not* have remarkable LFT changes.\n\nTriple-phase CT - indicated when?\n\nMalignant culture-negative neutrocytic ascites - case reports in 2017 and 2019, no clear guidance for management\n\n# Case 2:\n\nbeta-D-glucan - invasive fungal infx test, takes time to result (how long? how good?)\n\nGMS stain - identifies many kinds of fungi, pathologists mostly report morphology with possibilities that require clinical correlation \u003chttps://cmr.asm.org/content/24/2/247\u003e\n\n## pneumocystis jirovecii pneumonia in non-HIV infx pts\n\nStem cell tx, solid organ tx, heme malignancies, high-dose steroids, immunosuppression\n\nRisk for solid organ tx depends on tx, ?mostly d/t degree of immunosuppression\n\nPresents with nonspecific sx: dysnpea, fever, dry cough, hypoxia out of proportion to level of distress (this last point a personal obs from presenter - mb worth a study!)\n\nDefinitive dx with GMS from sputum or BAL, direct fluorescent antibody, PCR (PCR may have higher diagnostic yield)\n\nPresumptive dx (may be too hypoxic for bronchoscopy): increased beta-D-glucan, radiographic findings, clinical features, possibly increased LDH, and r/o other fungal causes\n\nFirstline tx: TMP-SMX 15-20mg/kg, desensitize if minor allergy+steroids if severe (low PaO2 or requiring supplemental O2)\n\nSecondline tx: clindamycin+primaquine; clindamycin+primaquine or TMP + dapsone if moderate; 21 total days.\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2020-07-06-noon-conference":{"title":"","content":"# Acute respiratory failure (most of this in Vandy handbook)\n\n## Modes of oxygen\n\n- NC - up to ~6L, ~40% FiO2\n- HFNC - up to ~15L, 80% FiO2\n- Venti mask - not used often, controlled with attachable and switchable filters\n- Non-rebreather - up to ~100% FiO2, turn flow up all the way, fill up reservoir first then apply\n- bipap - usu ICU, careful with aspiration risk, can adjust insp/exp pressures, up to 100% FiO2\n- optiflow - up to 60L, 100% FiO2, usu ICU\n\n## Get help\n\n- Esp if res-interning, don't hesitate to call/ask nurse to call Rapid Response Team (1-1111)\n\n## Differential\n\n(pt with known COPD desatting)\n\n- Most likely: COPD; other most common: CHF; must not miss: PE\n\n## Order\n\n- CXR, EKG, trop, BNP\n- bipap (not available on regular nursing floors), duonebs, lasix\n\n\n## COPD exacerbation\n\n- fairly algorithmic:\n    - bipap\n    - O2 for sat 90-94%, or \u003e88% if on O2 at home\n    - Prednisone 40mg x 5d\n    - Albuterol/ipatropium q4-q6\n    - abx\n\n\n## LASIX\n\n- feel free to give big push (e.g. 160) of lasix if any concern for volume overload\n- even if AKI - oxygenation takes priority, can rehydrate kidneys later\n\n## Anaphylaxis\n\n- call RRT (have friends - pt can need intubation, etc.)\n- 0.3mg of 1mg/ml IM epinephrine (on crash carts) (if not responding, put on drip)\n- O2\n- stop offending meds/infusions\n\n\n## PE\n\n- ddx: PE, pneumonia, STEMI, PTX (hence EKG, CTA or CXR if can't get CTA quickly, trop, BNP)\n- if AKI: can get VQ scan instead of CTA, but if suspicion is high start treating\n- massive (+hypotension): catheter-directed thrombolysis\n- submassive (normotensive, RV dysfxn + inc trop or BNP): heparin gtt or lovenox (preferred if possible - therapeutic more quickly with less futzing)\n\n## Afib w RVR\n\n- HR \u003e120 and stable: IV metop 5mg (up to 3x @ 5min intervals) or dilt (avoid if reduced EF, and often don't know, so usu metop)\n- HR \u003c120 and stable: oral metop tartrate 25mg\n- unstable: cardioversion\n- also something about amio drip that I missed, usu done in MICU/CCU\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2020-08-27-advance-care-planning-yakes":{"title":"","content":"# Advance Care Planning\n\nBeth Ann Yakes, MD\n\n## Advance directives (AD)\n\nAdvance directives can cross state boundaries.\n\nTN\n- spouse\n- adult children\n- parents\n- siblings\n- other interested family/friends\n\n(this is especially important for commonlaw or other SOs,\nthat may fall to the bottom of the list if not explicitly denoted in the AD)\n\nIf any part of the AD is not adequate to define your wishes, write it out.\nYou can attach as many pages as you'd like.\n\n\"If I can eat ice cream AND watch football, keep me alive.\nIf I can't do one, the other, or both of these, let me die.\"\n\nRe tube feeding/IV fluids:\nEnd of life nutrition is very different than what they feel currently when hangry.\nTube feeds often have gnarly adverse effects, e.g. gastroparesis leading to emesis leading to aspiration.\nAlso, what to do with the output? -\u003e irritation, ulcers, needing debridement, etc.\nIV fluids can lead to edema, more need for catheters, etc.\n\nRe CPR:\nThe provision to not resuscitate only comes into effect when the quality of life conditions are met.\n\n(TRIAD study - physicians got the decision to resuscitate wrong ~50% of the time bc they misunderstood AD relative to irreversible conditions)\n\n\n## Physician orders for scope of tx (POST)\n\nTake effect immediately upon signing, unlike AD that only come into play when the outlined conditions are met.\nE.g. healthy 90yo elects to not receive CPR regardless of reversible or irreversible conditions,\nfill out a POST, sign it -\u003e 90yo codes 2 minutes later, do not do CPR.\n\nPut it on your fridge! Make it easy to find if found down.\n\nAnyone who comes in from a group home has to have an active POST\n(may say do everything, but has to exist).\n\nHave to be a physician to sign this form.\n\nOK to provide copies in any requested language,\nbut most states require the form be in English to be valid,\nso that any provider can read it.\n\nlast updated: 2020-08-27\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2020-08-27-coding-billing-yakes":{"title":"","content":"# Coding and Billing\n\nBeth Ann Yakes, who is awesome.\n\nICD-10 Codes\n- International Classification of Diseases\n\nCPT\n- Descriptive terms and their codes to identify medical, surgical, and diagnostic services and procedures\n\nE\u0026M service codes\n- CPT codes\n- Evaluation and Management Codes\n\nPreventive service codes\n- CPT codes for annual physical, non-medicare\n\n## E\u0026M codes\n\n- history\n- exam\n- Medical Decision Making (MDM) (or Time in 2021)\n\n\nHx\n- CC and HPI\n- ROS\n- PFSH\n\nExam\n- # organ systems (out of 12 possible)\n\nMDM\n- # and complexity of problems addressed\n- amount of data/complexity analyzed\n- risk level to pt\n\nIf established patient,\ndoes not need to have *both* hx or exam,\ncan have one or the other.\n\nMoney amounts listed are for the professional fees,\nnot necessarily including hospital fees, etc.\n\nAverage clinic day:\n12 pts, ~2 $75, ~8 $110, ~2 $150 = ~$150 + $880 + $300 = ~$1330/day produced per provider\n\n99213 (\"level 3\") ~$75.\n\n- 1 HPI (pt is here for sore throat)\n- 1 ROS (pt denies fever or chills)\n- no PFSH\n- 2 PE (general: pt looks well, HEENT: no exudates, mild erythema)\n- 2/3 of the following\n    - address 2 minor/1 stable/1 acute uncomplicated problem\n    - review 2 pieces of data or use an independent historian (e.g. collateral from spouse)\n    - low risk tx and dx tests (e.g. OTC, simple PE maneuvers)\n\n99214 (\"level 4\") ~$110 (annual physical also about this amount).\n\n- this is the level to keep in mind for notes, even if the MDM is level 3, just to cover your bases\n- 4 HPI (1. pt has not had CP or SOB, 2. pt has had normotension, 3. pt has been compliant with their medicines, 4. something else)\n- 2 ROS\n- 1 PFSH (at least copy and paste from old note, or click \"mark as reviewed\" - does NOT need to be an actual update)\n- 5 PE\n- 2/3 of the following\n    - address 2 stable/1 worsening/1 new w systemic sx/complicated hx/uncertain prognosis)\n    - review 3 pieces of data (inc ind historian), or interpret (I reviewed the CXR and do not see pna) (it's also ok to be wrong, just give good-faith effort) (lab data doesn't count, has to be radiographic or similar), or confer (does not have to be verbal conference - could be chart review of specialist's note)\n    - moderate risk tx and dx tests (rx meds - could be \"cont lisinopril\", social determinants limit options, elective surgery w/o major risks)\n\n99215 (\"level 5\") - ~$150.\n\n- 4 HPI\n- 10 ROS\n- 2 PFSH\n- 8 PE\n- 2/3 of the following\n    - 1 severe worsening or threat-imposing new problem\n    - 2/3 of what is listed in moderate\n    - higher risk tx or dx (rx req monitoring e.g. coumadin/opioids/chemo, hospitalization, emergent surgery)\n\n\n## Preventive service codes\n\nAnnual physical - ~$110.\n\n- No CC/HPI\n- 14 ROS\n- PMH, FH, SH (c/p or \"mark as reviewed\" is sufficient)\n- address risk factors appropriate to age\n- multi-system PE targeted to pt\n- a/p including counseling, anticipatory guidance, risk factor mitigation\n- Identify note as \"Preventive annual exam\"\n- ICD-10: Z00.00\n- can add other ICD-10 codes as needed\n- billing code based on pt age\n    - 99395: 18-40\n    - 99396: 41-64\n    - 99397: \u003e65, not medicare\n- no co-pay! (if w/in calendar year vs 365 days, depending on insurance provider)\n- tell the pt if you're not going to code the visit as annual physical, bc they'll be charged\n- can also bill for annual + problem (e.g. 99396 Z00.00 + 99213 R07.89 [CP])\n\nCoding based on counseling time\n\n- Lvl 3: 15min\n- Lvl 4: 25min\n- Lvl 5: 40min\n- state \"I spent X minutes with the pt with \u003e50% spent on counseling regarding Y issue. We went over A, B, C, answered questions about Q, did teachback...\"\n- pick the highest billing lvl bw coding based on time or based on problem severity (e.g. lvl 3 prob, lvl 5 counseling)\n- in Jan 2021, may be able to count time spent preparing for visit and reviewing afterward, as well as in-person time\n\nlast updated: 2020-08-27\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2020-08-27-grand-rounds":{"title":"","content":"# Microbiome\n\nVincent B Young MD PhD, Ann Arbor\n\nMicrobiome: community of microbes and environment they inhabit\n\nMicrobiota: the microbes themselves\n\nFocus on C. Diff\n\n2-3% of healthy outpts have identifiable, toxin-producing C. Diff\n\n\"Antibiotic Associated Colitis\" 1977 papers that first described C. Diff related to abx, using hamsters as a model organism.\n\n\"An Epidemic, Toxin Gene-Variant Strain of Clostridium difficile\" 2005 NEJM\n\nC diff dx: PCR/LAMP, glutamate dehydrogenase testing (GDH) two vs three step, EIA for toxins.\n\nControversy: Nucleic acid amplification tests (NAAT) cannot distinguish colonization vs infx (NAAT does detect toxin gene).\n\n20-30% of pts will test + for NAAT during hospitalization (?colonization, spore passing through).\n\nControversy: should we use the most sensitive test (NAAT) to find even colonization, to control spread?\nOr use toxin tests up front, to catch the cases severe enough to produce detectable toxin? (i.e. use a purposefully less sensitive test that is possibly more specific for more severe dz)\n\nClassifying severe/complicated CDI\n- Severe: WBC \u003e15k, Cr \u003e1.5x normal, absolute serum Cr \u003e1.5 if no baseline available\n- Fulminant: hypotn, shock, ileus, toxi megacolon\n- Recurrent: 2-8wks from last positive specimen OR clinical response\n\nStudying microbiome\n- Anatomy\n    - structure: \"who is there?\"\n- Physiology:\n    - actual function: \"what is it doing?\"\n    - potential function: \"what can it do?\"\n\n- 75-80% of tx cases do not recur; 20-25% of cases recur and have worse outcomes.\n    - theory: pts never return to normal microbiota, hence if restore normal microbiota -\u003e cure\n\n\n- Hx fecal tx (Fecal Microbiota Transplantation, FMT)\n    - Pliny the Elder: fermented milk and fecal tx\n    - Ge Hong: 4th C\n    - another guy whose name I didn't catch: \"yellow soup\" == poop supernatant\n    - surgeons in 50s: successful fecal tx for abx-associated\n    - 2013 NEJM: 94% success rate for FMT (16pts), 30% vanco, trial ended early\n\n- Prior to FMT, community is \"less diverse\" than donors\n- FMT results in transfer of community structure to pts\n- Structure does NOT predict function - some pts who do *not* recover do have more diverse micriobiota, and some pts who *do* recover remain less diverse\n\nMicrobiome -\u003e metabolome, and metabolome significantly contributes to generation of spores vs inhibition of infx\n\nMice != humans, mouse microbiome != human microbiome.\nHuman feces known to be effective in tx CDI in humans is not effective in tx recurrent CDI in mice.\nMouse FMT restores bile acid metabolism in mice, thought to be the main mxn.\n\nJenna Wiens, PhD: ML for microbiome. 2018 Infx ctl and hosp epi, \"A Generalizable, Data-Driven Approach to Predict Daily Risk of...\"\n\nA generalizable approach vs a generalizable model.\nYES.\n(You can feed hospital-specific data to the same code, with some variation in preprocessing, and have a new model using a generalizable approach).\n\nWiens now doing prospective work - YES again.\n\n\nNext steps\n- moving from association to causation\n- precision medicine that includes host genome and microbiota genomes, etc.\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-08-12-morning-report":{"title":"","content":"# nausea, vomiting, fever, and a fall\n\n67F with T2DM (well-controlled w/o insulin), hypoTh, asthma, presented after 3d n/v, with lightheadedness, weakness, low-grade fever, and a fall.\n\nDenies hitting head.\n\nAt baseline previously.\n\n100.3F at home. No sick contacts. Non-productive cough, also x3d.\n\nNo new meds. No known inciting events.\n\nWoke up and called a friend (not found down).\n\nOSH - hypotensive, given zosyn and 2L LR\n\n# SHx\n- 2-4 beers/day\n\n# PMHx\n- T2DM\n- asthma\n- depression\n- osteoporosis\n\n# Meds\n- metformin\n- synthroid\n- lexapro\n- inhalers\n- fosamax\n\n# VS\nHypotensive, tachypnea\nOn pressors\n\n# PE\ntachycardic, tachypneic, fairly warm, AOxSelf, still following commands\n\n\n# Data\n- WBC 2.4, Hgb 10.7, Plt 28\n- COVID -ve\n- Bicarb 12, Cr 1.7\n- Bili 2.8, D bili 2.3\n- ALK/AST/ALT elevated\n- 7.3/33\n- LA 4.5\n\n# ... went to huddle, missed a bunch...\n\n\n# Dx\n\nEhrlichiosis! Tx w doxy.\n\nTime to diagnosis is delayed in pts who require ICU admission (Kuriakose 2020, JAMA Network Open, e202577)\n\n# Pearls\n\nFor RMSF, no need to send w/u unless clear geographic exposure.\n\nSend Ehrlichia/anaplasmosis PCR, smear, consider babesia.\n\nLyme: should have travelled north of the Mason-Dixon line, not endemic to TN.\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-10-28-adrenal-disorders":{"title":"","content":"# Adrenal disorders\n\nDr Mona Mashayekhi MD, PhD\n\n---\n\n## Overview of adrenal insufficiency\n\n|          | ACTH | Cortisol | Aldosterone | Renin | DHEA       |   Na   |  K  |  ACTH stim  |\n|----------|------|----------|-------------|-------|------------|--------|-----|-------------|\n| Primary  | high |   low    | low         | high  | low        | low    |high | nonreactive |\n| Central  | low  |   low    | wnl         | wnl   | low-normal*| low**  | wnl | reactive $  |\n\n\n\\* DHEA has some response to ACTH\n\n\\*\\* via DDAVP, less extreme hypoNa compared to primary\n\n$ if longstanding central process, ACTH stim will *not* be normal d/t atrophy\n\nSheehan - ACTH zero, cortisol zero, ACTH stim will be normal (no time yet for atrophy)\n\n\n## Primary adrenal insufficiency\n\npost-op, infx, hemorrhage, mets, autoimmune\n\nMore electrolyte abnormalities d/t aldosterone problems (ENAC -\u003e K up, Na down, also some vessel tonicity -\u003e HoTN)\n\n## Secondary adrenal insufficiency (central)\n\nE.g. chronic steroids (causes 1, 2, 3 of AI are iatrogenic d/t steroid use), Sheehans\n\nACTH cleaved to POMC, melanocortin -\u003e hyperpigmentation (palms more specific)\n\n### Primary AI tx\n\nPrefer hydrocortisone, \nas has short half-life and allows closer mimicry of physiologic levels. \nHigher AM dose, lower PM dose.\n\nRelative half-lives and physiologic doses of steroids:\n\n|       | dose        | t 1/2 |\n|-------|-------------|-------|\n| dex   | 0.25mg      | +++   |\n| pred  | 4mg         | ++    |\n| hydro | ?           | +     |\n\n\n---\n\n\n## Primary hyperaldosteronism\n\nCommon, should suspect if low K and resistant HTN.\n\nMany BP meds modulate HPA axis in some way or another, \npractically only MRAs are considered sufficiently problematic to interfere with standard testing.\n\nStart with aldo/renin ratio.\n\n### Primary hyperaldosteronism tx\n\nPrimary therapy is surgical.\n\nMRA therapy can be helpful, \nbut does not prevent other effect of unopposed aldosterone (e.g. cardiac),\nso preferred when pts are not surgical candidates.\n\nFor maximum effectiveness, titrate MRA dose to level of renin.\n\nAdrenal venous sampling (AVS) - done by interventional radiology, highly specialized even within IR.\n\nSo some places, if \u003c40yo, will just use CT evidence of nodule to justify removal. \n(if \u003e40yo, high  likelihood of benign adenoma)\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-10-28-transgender-medicine":{"title":"","content":"# Transgender medicine\n\n[\"academic half day\", \"transgender\", \"primary care\"]\n\nShayne Taylor, MD\n\n## Disparities\n\n- insurance\n- knowledge\n- bad care\n- disease burden\n  - trauma-informed care\n\n### insurance\n\nInsurance often won't cover the visit if the primary dx is e.g. \"Gender Dysphoria,\"\nhave to bill it as \"HTN\", \"Endocrine Disorder NOS\", \"Therapeutic Monitoring,\" etc.\n\nInsurance problems even problematic for procedures.\n\nAlso, transgender people need \ntwo letters of mental health support \nfor any procedures below the belly-button (e.g. TVH). \nAlso, wtf.\n\n### knowledge\n\nKnowledge gaps for patients, providers, insurance as above.\nEven if well-meaning, physicians typically know too little or are uncomfortable.\n\n### bad care\n\n1/2 trans women in the South is HIV+, and of those, \noutcomes are worse compared with the cis population.\n\n## language\n\n### pronouns\n\nIntroducing ourselves with pronouns normalizes the process.\n\nAsk directly, \n\"Hi Emily, nice to meet you, what pronouns do you use?\"\n\nDocumentation in Epic is getting better, \nwill hopefully be part of the standard intake soon.\n\n### anatomy\n\nUse functional terms that have medical meaning - \n\n\"people who menstruate,\" \n\"people with a cervix,\"\n\n### intimacy\n\nRegarding the act of sex, think about:\n\n1. do we need to modify the chances of getting pregnant?\n2. do we need to mitigate the risk of HIV?\n3. do you feel safe?\n\n## medications\n\nBottom line is medical therapy for gender dysphoria is life-saving.\n\nSecondarily, \nregarding risk reduction, \nmany people will buy hormones online if no provider will rx,\nso better part of valor is to have open conversation, \nrx meds with appropriate mitigations as possible, \nmonitor closely.\n\n### Transgender men\n\n(assigned female at birth, identifies as male)\n\nEssentially, one drug: testosterone.\n\n- CBC, CMP, A1c, lipids, bHCG (if they have sex with penis people).\n- Consent is in MedEx (risk of HTN, increased blood glucose, increased lipids, ?increased risk ASCVD/CVA [contested])\n- permanent changes: facial hair, body hair, male pattern baldness, voice lowering, clitoral growth\n- temporary changes: acne, irritability, sex drive, secondary amenorrhea, lab changes, male pattern fat deposition\n\nForms: Testosterone cypionate/enanthate\n\nOverall strategy:\n\n- q14d 0.25mL (50mg) starting\n- in 2-3mo, get HCT, total T (goal 400-700 mid-injection)\n- will likely be low, move to q7d (i.e. double dose)\n- then go to q7d 0.4mL (80mg) (some do 100mg, but seems to have more adverse effects)\n- some folks like q14d dosing instead, some folks like IM injections - accommodate!\n\nReassess every few years to see if the permanent changes are where they'd like, \nif they're ok with the temporary changes reverting, would like hysterectomy, etc.\n\nGenerally FDA approved for MSK injection, \nbut subQ works and is easier for pts \n(may have to talk to pharm about getting the right needles).\n\nMain issue with gel is the expense, coupons exist (good for needlephobes).\nSecondary concern is transfer to close contacts.\n\nBirth control: prefer progesterone-only, IUD, Nexplanon\n\n(for unknown reasons, \nIUDs in people who are on T therapy are associated with pelvic pain, \npain w orgasm, \nso Nexplanon is a great option)\n\n### Transgender women\n\n(assigned male at birth, identifies as female)\n\nTwo goals: block T, add E2\n\nBlock T: \n- spironolactone @ 100mg daily typically, can go to BID (keep an eye on K, etc.)\n- bicalutamide @ 50mg - designed for metastatic prostate cancer, monitor CMP\n- goal T \u003c 50 (may have higher goal if still wants to have sex)\n\nAdd E2:\n- estradiol, prefer patches d/t lowest risk of CVA\n  - patch: vivelle dot (0.05 2x/wk, 0.1 2x/wk, 2x0.1 2x/wk, can go higher but becomes logistically difficult)\n  - pills: 2mg, 4mg, 6mg, 8mg max. Can take SL, but will have to take more often. Careful with lab checking, variability is high.\n  - injections: estradiol valerate/cypionate, q7d 0.2-0.3mL (3-6mg)\n- level: society guidelines 100-200, practical 200-300 may be more effective, but overall go by symptoms\n\n?progesterone\n- expert opinion varies\n- online opinion is pro\n- may help w breast development\n- 200mg (PO vs PR) qHS (causes some somnolence)\n- try for 6mo, reassess (cont if good, d/c if equivocal)\n\nCancer screening: \npap smears (atrophic, let the pathologist know this is a transgender pt), \nget HPV co-test, \nmammograms as indicated\n\nAlso consider sperm banking (expensive, not always desired, but worth discussing).\n\n## surgeries\n\n### Transgender men\n\nBreast removal, very helpful.\nUsually requires 1 letter from mental health specialist.\nCash price is $8500 at VUMC if insurance won't cover.\n\nTVH: prefer keeping ovaries for long-term bone protection, etc.\n\nMetoidioplasty - release the clitoris enlarged by T therapy, \ncan reroute urethra (frequent complications, but can urinate standing up),\nnot large enough for penetrative sex.\n\nPhalloplasty - TVH first, graft from forearm skin, \nurethral lengthening (also frequent complications, \ne.g. require I/O cath, SPC), penile implants possible for penetrative sex.\n\n\n### Transgender women\n\nBreast augmentation - well-tolerated, few downsides\n\nOrchiectomy - well tolerated, will also need lifelong HRT\n\nVaginoplasty\n- shallow depth, cosmetic but no penetrative depth, few downsides\n- full depth, needs full electrolysis of scrotum to create vaginal shaft, then needs dilation forever (prevent spontaneous closure, immediately post-op 3-4x/day for 30-45 minutes)\n\n\n## Inpatient care\n\nUnless clear indication to stop, \nwhich would be rare \n(?estrogen iso CVA, but even then probably ok to continue),\ncontinue their hormones inpatient.\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-11-08-mr-muhs":{"title":"","content":"# Morning Report\n\n\n# Case 1\n\nDr Amelia Muhs\n\nCC: 1wk flank pain, dark urine, dyspnea\n\nHPI: 24F 1wk b/l flank pain, dark urine, subjective fever x1wk, \n+intermittent dyspnea, no productive cough.\n\nROS: 30lb unintentional wt loss over 6mo, \nnight sweats 5-6 nights/wk,\nno measured fevers,\nintermittent hip and knee pain after work,\nno [rashes, throat pain, HA, n/v]\n\nPMH: COVID 8mo ago, tx for bartonella w azithro 1mo ago\n\nMeds: none\n\nFH: maternal grandmother (Graves)\n\nSocial: no tobacco, 2-3 EtOH/wk, vapes mj 1-2x/wk, work: vet tech\n\nExam:\n\nwnl other than 101.8F, 102 HR, wt 105lb, 65\"\n\nLabs:\nWBC 14.3 (90% PMN), ALK 205, Cr 0.8, UA wnl, Ferritin 803, D bili 1.8, CRP 303, ESR 79\n\nHuge infx w/u -ve (tularemia didn't get sent, on accident), rheum w/u -ve other than ANA 1:160.\n\nGot better rapidly w LVQ (did not get better w 1d CAP covg, 1-2d vanc-cefe).\n\nPresumed dx: Legionella\n\n## Legionella and other atypical pna\n\nLegionella\n\nw/u: \n- BAL/tissue/pleural fluid cx, needs buffered charcoal yeast extract agar, 4-5d process, sens 20-80, spec 100%\n- U Ag test: only detects serogroup 1, sens 70-80%, \n\nAtypical pna: 22% CAP in US. legionella pneumophila (U Ag), chlamydia pneumoniae (PCR - remains + for months to a year), mycoplasma pneumoniae (PCR)\n\n\nOther learning points:\n- renal failure in young female needs formal pelvic eval, cervical cancer can met to LN and cause obstruction\n\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-11-10-mr-sunthankar":{"title":"","content":"# Morning Report\n\nKatie Sunthankar, MD\n\n# case\n\nCC: Fever\n\nHPI: \n~30F, \n2d general body aches,\nTMax 103.8, \nnausea, \ndiffuse abd pain and HA.\nUnresponsive to APAP.\nNBNB emesis -\u003e presentation VUMC ED.\nUTI x2, 4 and 2 wk PTA, tx w macrobid and bactrim.\nUTI sx never truly resolved.\nRecently returned from glamping trip in the MidWest,\n3wk prior to now.\n\nPMHx/PSHx: none\nMeds: OCPs\nFHx: Dad w afib, sis w eczema/scoliosis, PGF leukemia\nSHx: from northern Europe (here for \u003e10y), \n1ppd x2y, \nno pets, \nlittle EtOH, \nworks in an office setting\n\nExam:\n100.9F, HR 149, BP 120/70, on RA\nHEENT: mildly red tonsils, tender anterior cervical LA\nAbd: suprapubic tenderness\nSkin: no rashes\n\nLabs:\nNa 133, WBC 1.1, Hgb 13.2, plt 233 (CBC 6-7mo prior totally wnl)\nANC 0.0, ALC 920, 3% atypical lymphs, no blasts\nLFTs fine.\nUA: +ketones, +bili (no urobilinogen), \u003e500 protein\nUPC: 0.2 grams/day\nCRP: 252\nHuge infx (tickborne, viral, urine/serum fungal), w/u -ve.\n\n## Dx: \nAgranulocytosis d/t bactrim\n\n### Agranulocytosis\n\nANC \u003c200.\n\nInherited: BEN, familial neutropenia, congenital neutropenia\n\nInfx: HIV, EBV, CMV, HHV6, measles, rubella, varicella, brucella, tularemia, TB, shigella, anaplasmosis, \n\nDrugs: \n- weeks-months after initiation of drug, typically ~4wks, 2-15 cases/y/10^6 people, mean age 51, M==F\n- anti-thyroid (PTU, _MMI_), psych: _clozapine_ (MCC), antibacterial (_bactrim_, macrolides, cephalo, dapsone, penicillin), NSAIDs, colchicine, _sulfasalazine_\n\nMoA drug-induced: not clear, two hypotheses (good review in Blood)\n- hapten (covalent binding to cell surface protein by reactive metabolites)\n- danger signal (+inflammasome by drug-protein conjugates w/in PMN, +oxidized)\n- some GWAS studies underway, may have association w HLA\n\nDuration - mean 8d, but can be much longer\n\nPresentation - ~50% present w infx\n\nBMBx - usually hypoplastic, but could be hyperplastic or have other goofiness\n\nOutcomes - possibly improved over the years. No significant difference wwo GCSF, however most folks do get GCSF.\n\nSome learning points:\n- acute toxo can look exactly like mono, down to splenomegaly\n- no one should die w/o a dose of doxy\n- don't mix azathioprine w allopurinol\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-11-22-mr":{"title":"","content":"# Morning Report\n\n## Case\n\nCC: HA, vision loss 4mo\n\nHPI: \n64F, Korean, healthy (minor arthritis).\nDeveloped daily HA 4mo, intermittent but can last all day.\n+jaw claudication, TTP both sides of head. Not positional. APAP w/o much improvement.\nNo aura, some +n/v.\n1mo vision loss R eye lateral fields, blurry; R leg weakness, cannot lift leg.\nDaily subjective fevers, \nMild weight loss.\n\nPCP started pred 20 2-3d with some improvement in arthralgias. \n\nPMH: \nHTN, OA\n\nMeds: \nlisinopril, pred 20 2-3d\n\nFH: \nnot much known\n\nSHx: \nmoved from Korea in 1980s, no smoking, no EtOH, works as seamstress\n\nPE:\nvss af, +proximal muscle weakness 2/5 R leg, plantar/dorsiflexion intact, sensation wnl. Reflexes 2+. \nVisual fields R sided lateral weakness, nondilated exam w/o macular edema. No rash, all joints wnl.\n\nLabs: Na 129, CBC 11.7, CRP low, ESR 3, INR wnl, LFT wnl.\n\nCXR: L apical PTX. \nCT: 1.8cm LUL mass, spiculated w pleural tenting.\nMRI brain/C spine: L lateral transverse sinus filling defect (not clearly thrombus)\n\n### Pearls\n\n- GCA ~20% have ESR wnl.\n- GCA is MCC otherwise unexplained fever \u003e3wk in adults \u003e60yo (~30%)\n- ESR is primarily measure of fibrinogen concentration, unlikely to drop fast w a few days of relatively low-dose steroids\n- some series describe an increased incidence of malignancy w/in 6-12mo of GCA dx, however it appears this may be mostly d/t increased follow-up and extensive workup\n\n\n## Case\n\nEos 5200. \n\nDRESS Dx criteria\n- RegiSCAR score:\n  - fever \u003e100.4\n  - LA\n  - eos\n  - \u003e50% BSA rash or bx proven\n  - organ involvement (liver, kidney, lung, heart, muscle, pancreas)\n  - duration \u003e15d\n  - exclusion of other causes (list of labs that need ordered)\n\nPREDICT-1 trial (HLA-B*5701 screening for ABC hypersensitivity)\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-11-22-noon-conf-acid-base-arroyo":{"title":"","content":"# Acid-base\n\nJP Arroyo\n\nH+ + HCO3- \u003c---\u003e H2O + CO2 ---\u003e Vm\n\nMinute ventilation is a key but often overlooked part of the equation, \nneed escape route for CO2.\n\nsugar + O2 ---\u003e ATP + CO2 + H2O \u003c---\u003e H+ + HCO3- ---\u003e CO2 ---\u003e lungs ---\u003e the world\n\nCO2 is a volatile acid, bc its H+ was donated.\n\nNonvolatile acids: H2SO4 (e.g. muscle breakdown), HCl\n\nKidney's roles in acid-base:\n\nCirculating: HCO3- 24meQ/L\nAcid production: 1 mEq H+/kg/day\n\nOffset acid production by:\n\n1. reabsorb HCO3-\n2. make new HCO3-\n3. excrete H+\n\n## acid base interpretation\n\nABG HCO3- is trustworthy, need a concomitant BMP to assess true anion gap\n\n1. internal consistency (ABG and BMP should be drawn close temporally, results w/in about 2mEq)\n2. ?pH - \u003c7.35 or \u003e7.45\n3. assess for primary disorder, (is the compensation appropriate)?\n  - most concerning/difficult/common in sick patients is metabolic acidosis\n  - metabolic acidosis: low HCO3-\n  - metabolic acidosis ---\u003e increased Vm\n  - 1.5(HCO3-) + 8 +/- 2 = predicted CO2\n4. AG (Na+ - (Cl- + HCO3-)) should be ~10\n5. dAG + HCO3- (delta anion gap plus bicarb)\n\n\nPractical: loaded ABG are ok, just don't directly compare the loaded ABG w the same time BMP (use one or the other as able)\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2021-11-29-noon-conference":{"title":"","content":"\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2022-04-28-anxiety-psychopharmacology":{"title":"","content":"# anxiety\n\n\n## mostly happy and mostly functional\n\nDefine goal (which is not perfection),\nrecognize deviations,\nand degrees of deviation\nthat warrant intervention.\n\nGeneral goals:\nStay aligned with core values,\nparticipate in meaning-making activities,\ndeal with issues with minimal disruption\n(relative to the magnitude of the issue)\nand get back to function.\n\n\n## waves of anxiety\n\nMoments that correspond w peak anxiety symptoms,\nwhich make it difficult to stay aligned w core values and perform meaning-making activities.\n\n\n### situations\n\n- triggers (sensual stimulus related to prior negative experience)\n- giving a presentation\n- taking an exam\n- starting on a particular rotation\n- plane flight\n\n\n### symptoms\n\n- heart racing\n- feeling of loss of control\n- sweating\n- inability to focus\n- difficulty sleeping\n- fatigue\n\n\n### actions\n\nActions that move us toward or away from \ncore values and meaning-making,\ni.e., adaptive vs maladaptive actions.\n\nDifferentiating toward/away actions can be subtle,\ne.g. going to get a drink with a friend could be productive or destructive.\n\n\n## specific disorders\n\nMany. \n\nDefining dx may help get a general sense of which neurotransmitters to modulate,\nwhich meds and other approaches to try first.\n\n- Panic disorder (4+ wks of panic attacks and maladaptation to them)\n- Generalized Anxiety Disorder (3+ sx \u003e=6mo)\n- Social Anxiety Disorder (\u003e=6mo)\n- Specific Phobia (\u003e=6mo)\n- Neurodevelopmental disorders (e.g. ADHD dx during the pandemic - is the current situation adult-onset anxiety or unmasking latent issues?)\n\n\n## management\n\nModify the situation, symptoms, and/or actions to improve outcomes.\n\nDefine a goal and manage expectations, similar to pain mgmt.\nWill not be able to get to 0/10 anxiety,\nbut going from 10/10 to 6/10 may allow \nregain of meaningful function.\n\n\n## management of management\n\nMost SSRIs can also be activating at first,\nso communicate this to the patient\nand consider a prn for peaks (benzos, buspirone).\n\nRecognize that benzos are like afrin - \nwork like gangbusters, and fast,\nbut long-term they tend to worsen the problem.\nDefine course of treatment \n(e.g. while we are waiting the 4-6 wks for the SSRI to fully kick in),\ndefine specific situations.\nScreen for substance use disorders\nand family history \n(very small percentage of people\nwill go on to develop de novo substance use disorder \nwith rx benzos).\n\nSexual dysfunction from any psychotropic medicine \ndoes not generally get better over time,\nconsider adding buspirone \u003e=30mg to help w this.\n\nStopping at \u003c6mo is associated with higher degree of relapse,\nso if any benefit is derived from therapy try to continue for 6mo.\nIdeally work with a therapist to reinforce adaptive behaviors during those 6mo,\nand afterward consider whether a taper of medicine is likely to allow the person to maintain goals.\n\n---\n\n# psychopharmacology\n\nFDA labels for drugs are general.\n50mg of IR quetiapine, 37.5mg XR venlafaxine \ndo not map exactly onto what we usually call them\n(second generation antipsychotic and SNRI).\n\n## second generation/atypical antipsychotics\n\n## pathways of clinical relevance\n\n- Mesolimbic - D2 (need \u003e=60% blockage for efficacy)\n- Nigrostriatal - Parkinsonism, akathisia, tardive dyskinesia\n- Mesocortical - apathy, inattention\n- Tubuloinfundibular - galactorrhea\n\n## receptors \"\" \"\"\n\n- D2 - agonism increases nausea (carbidopa-levodopa brand name chosen as marketing tactic for having less GI adverse effects \"Sinemet\" == \"no puke\")\n- 5HT2a - antagonism: decreases EPS\n- H1 - antagonism: sedation, decrease itching, wt gain, anxiolysis, weight gain, decreases nausea\n- M1 - antagonism: confusion, sedation, dries, decreases nausea\n- alpha1 - antagonism: orthostatic hypotension, sedation\n\nDrug naming schemes reflect receptor targets.\n\n- cloza   | pine\n- olanza  | pine    | H1, 5HT2a, M1, D2 (great for chemo-induced nausea, hits three relevant nausea receptors at low doses)\n- quetia  | pine    | H1, 5HT2a, M1     (less D2, not quite as good for nausea, but pretty great for agitation)\n- zipras  | idone\n- risper  | idone   | 5HT2a, alpha1, D2 (less weight gain, not much of a nausea medicine)\n\n## depression\n\n\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2022-05-06-hemoptysis":{"title":"","content":"# hemoptysis\n\nScott McCall\n\n\n## when to intubate\n\nif they've already coded, or are very close to it\n\nif a person is awake enough to cough, \nthey are better at clearing the small airways than we are with suction\n\n\n## ABCs\n\nA - late intubation\nA - mainstem/positioning (intubate the clear side, put the sick side down)\n\nB - \n\nC - ~3L of blood can fit in a typical lung, may need massive transfusion protocol\n\n\n## meds\n\nTXA - if the inhaled drug can get to the problematic areas, e.g. bronchitis/bronchiectasis\n  - literature suggests TXA is helpful if the coagulation cascade is relatively normal (e.g. no mortality benefit in cirrhosis)\n\nPCC vs FFP - \nno in vivo or in vitro evidence that \ndrug levels or coagulation parameters are meaningfully improved with PCC, \nXa decoy (Andexanet Alfa) does work but is expensive and not often stocked\n\nCryo\n\n\n## imaging\n\nCT bronchial artery protocol (CT angio w relatively early shots)\n\nGGO, can be tree-in-bud (clot)\n\n## causes\n\n- bronchitis/bronchiectasis (in bronchiectasis the vessels are closer to the surface)\n- PNA\n- PE (usu late, distal, scant, r/t necrosis)\n- malignancy - things that recruit VEG-F - thymic, thyroid (papillary), melanoma, Kaposi\n- cavitary lung lesions (TB, fungal balls, Erasmus formation)\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2022-05-09-vents":{"title":"","content":"# vents\n\nAlex Dragnich\n\n\n## overall\n\nArt Wheeler (paraphrased) - the best mode of ventilation is the mode you know best.\n\n\n## knobs\n\nMany!\n- FiO2\n- rate(t)\n- Pi\n- PEEP\n- I:E ratio\n- TV (Vt)\n- etc.\n\nbut really:\n- FiO2\n- triggers\n- Q (flow)\n- C (cycle)\n\nand cannot perfectly control pressure and volume at the same time,\nthough modes like PRVC attempt to strike an automated balance.\n\noxygenation: FiO2 (directly) and PEEP (via mean airway pressure)\n\nventilation: R(t), Vt, Pi\n\n\n## APRV \n  \nType of inverse ratio ventilation, \nbased on time constants of collapse/expiration.\n\ne.g. expire ~75% of TV in a time constant.\n\n\n## SIMV\n\nsupported intermittent mechanical ventilation. \n\nBackground of VC at a certain rate,\nallowed to take supported breaths in between.\n\n~CMV w BiPAP\n\n\n## AC\n\nassist control.\n\nvolume control, people are allowed to take breaths and then volume is delivered\n\nset: Vt, PEEP, R(t), FiO2\n\nmeasure: peak inspiratory pressures, plateau pressures, MV, driving pressure (plateau minus PEEP)\n\ntriggers: P or Q (e.g. neuromuscular, may not be able to generate much flow so set pressure trigger, COPD often the opposite)\n\ncycle: time\n\n\n## PC\n\nset: P(high), P(low), Pi, R(t)\n\nmeasure: Vt, V\n\ntriggers: P or Q\n\ncycle: time\n\nset a MV alarm (ideally, set at what has been maintaining ventilation for that pt)\n\n\n## PRVC\n\nset target volume, generates pressures, adjusts based on calculation of last three breaths\n\nis actually pressure control mode\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2022-05-10-troubleshooting-vents":{"title":"","content":"# troubleshooting vents\n\nScott McCall\n\n## high peak pressures\n\nStart at the machine.\n\nMake sure the system is working well - \ncheck tubes for kinks, \nfollow it all the way from the vent to the patient,\nlook for biting, etc.\n\nWithin the patient,\nthink about mucus plugs at the end of the ETT,\nsingle-lung intubation,\nmainstem intubation,\nPTX,\nhemothorax,\nARDS.\n\nGet: CXR, plateau pressure\n\n## low minute ventilation\n\nvent problem vs patient problem\n\nvent problem (are we actually having high peak pressures?)\n\npatient problem\n- is the cuff inflated?\n- has the patient been intubated for a long time (balloon migration, tube breakdown)?\n- bronchopleural fistula\n\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2022-05-13-pressors":{"title":"","content":"# pressors\n\n\nMAP = SVR * CO\n\nCO = HR * SV\n\n# receptors\n\nalpha1, beta1, beta2\n\nalpha1 = vessel walls, contracts\n\nbeta1 = contractility\n\nbeta2 = vasodilation, bronchodilation\n\nvasopressin/ADH = V1 (vasoconstriction in the periphery), V2 (in kidneys)\n\nAngII = inc aldosterone, peripheral vasoconstriction.  \n\n# drugs\n\nepi = +++alpha1, +++beta1, ++beta2. \nUseful during codes, anaphylaxis (bronchodilation), third(ish)-line in sepsis.\n\nnorepi = ++alpha1, ++beta1, no beta2. \nGo-to pressor. \n\nphenylephrine = +++alpha1, no beta1, no beta2. \nUseful pressor if tachyarrhythmia and not in cardiogenic shock.\n\ndobutamine = no alpha1, ++beta1, +beta2. \nUsed in cardiogenic shock (+chronotropy, +inotropy), pHTN.\n\ndopamine = not really used any more\n\nvasopressin (ADH) = mostly looking for V1 effects\n\nAngII = Used in septic shock. \nVery pt-dependent, \n\"super-responders\" (~10%) can sometimes come off all other pressors, \nmost folks don't respond much. \nC/i in heart failure. \nIncreases clotting (cannot use if cannot use DVT ppx).\n\nalso think about: \nstress-dose steroids (little downside, cortisol testing is useless in critically ill pts), \nacidosis (do they need bicarb drip/post-replacement bicarb?)\n\n\n# access\n\nPressors via PIVs are usually fine. \nNo actual dosage cutoff, \nsome institutions will create cutoffs \nbut there's no data for that.\n\nExtravasation rate ~3/1000 in one retrospective study of ~14,000 pts.\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2022-05-14-codes":{"title":"","content":"# codes\n\nAlex Dragnich\n\n\n## good codes\n\n- calm\n- closed communication\n- established roles\n- room logistics (number of humans needed == number of humans present, stools, move stuff)\n- no ego\n\n\n## roles\n\nEssential roles:\n\n- compressions\n- airway\n- timekeeper\n- code leader\n- meds\n- pulse (+/- doppler)\n- pharmacy\n\nSometimes:\n\n- procedures\n- ultrasound\n- logistics\n\n\n## first 30 seconds\n\n- compressions (assess for quality with whatever tools you have: ETCO2, a-line, tele, visual)\n- lock the bedboard\n- pads on \n- access (IO!)\n- airway\n\n\n## H's and T's\n\n- hypothermia\n- hypoxia\n- hyper/hypoK\n- H+\n- hypovolemia\n- hypoglycemia (bonus)\n\n- tension\n- tamponade\n- thrombus (coronary)\n- thrombus (pulmonary)\n- toxins\n\n\n## room management\n\n- loud room: \"Volume down in the code room.\"\n- crowded room: \"Those without an active role, exit the room.\"\n- things aren't getting done: closed loop communication, \"1mg of epi, please confirm when done.\"\n- someone is struggling with a task: redeploy them (e.g. compressions, contact family, etc.)\n\n\n## after the code\n\nDebrief.\n\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/2022-05-17-ards":{"title":"","content":"# ARDS\n\nGreta Dahlberg\n\n\n## criteria\n\n- acute (\u003c7d)\n- hypoxic (P/F ratio \u003c300)\n- b/l\n- not explained by cardiac failure/fluid overload\n\n[Berlin criteria calculator](https://www.mdcalc.com/berlin-criteria-acute-respiratory-distress-syndrome)\n\n\n## pathophysiology\n\nAlveolar macrophage overrecruitment --\u003e cytokines --\u003e PMNs, etc. --\u003e direct destruction, microthrombi\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/anki":{"title":"","content":"# anki\n:learn:vimwiki:\n\n# spaced repetition\nWouldn't it be nice if I could tag some statement, run a sed command, output to a csv, and import into Anki?\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/doing_science":{"title":"","content":"## On doing science\n\n### Mysteries vs puzzles\nhttps://adcontrarian.blogspot.com/2020/04/puzzles-and-mysteries.html\n\n[locally_saved_post](file:/home/beau/dox/surfed/puzzles-and-mysteries.html)\n\n\"Puzzles ... are problems for which there is not enough information. ... Mysteries are problems for which we have plenty of information, but no accurate analysis.\"\n\nGladwell gives an example of WWII, spies vs. the \"screwball division.\" Spies went to gather more information, screwball division analyzed already available data. Screwball division figured out the V-1 rocket had been developed, had been stalled, and accurately projected when it would be finished.\n\nIt seems like much of medical ML is this - we have SO MUCH data, but it hasn't been properly cleaned and analyzed. It's also often siloed and unavailable to the \"screwball division.\"\n\nFri 24 Apr 2020 08:13:53 AM CDT\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/dr_rose_on_ai_in_healthcare":{"title":"","content":"# dr_rose_on_ai_in_healthcare\n:lectures_2019:\n\nYou may find the stuff on \"opening the black box\" interesting - SHAP (their GitHub readme is great), Zhao and Hastie's paper on causal inference. For tree-based methods (e.g. random forests, gradient-boosting machines), explainability is fairly solved. For deep learning on images, explainability is also fairly straightorward. Deep learning on tabular data is far less solved (e.g. the Google readmission paper - had to use a handicapped version of their neural network for explainability, and even then was not super useful). Thankfully, tree-based methods are often as good or better in terms of performance on tabular data.\n\nIn my opinion, in all healthcare-facing ML, explainability methods should be baked into the pipeline. It's so easy now, literally a few more lines of code to generate the model that explains the model (incorporating the output in a meaningful way is a little more expensive in terms of code, but if I can figure it out then so can any researcher). The thing we should be building is not a model that is reapplied across systems, but a pipeline for data ingestion, model-building, and explanation that could be rapidly deployed in different systems (e.g. for internal testing and validation). This would still disadvantage poorer systems with less ability to collect data, but maybe not by much - everyone has CBCs, data on discharges and admissions, basic demographic information, etc., and almost everyone uses some kind of EMR.\n\nOn the anthropomorphic relationships with computers, have you heard about https://en.wikipedia.org/wiki/ELIZA ? It was developed in the 60s at MIT, simple rules-based conversation \"bot,\" and people developed deep personal connections, on a level equalling or exceeding the current relationships people are building with Alexa (I would argue exceeding, as the conversations were purposefully therapeutic and do not avoid sensitive subjects).\n\nWould be interested in thoughts on why, exactly, Google/Amazon/etc. are needed. We have clinician-scientists, PhD researchers, collaboration with other universities (e.g. CWRU has great comp-sci). We can do NLP, DL, whatever, on our own. Google would have some extra data on searches, all the stuff they can get from cookies, etc., phone data. Amazon would have similarly rich data. But we get into some of the same issues we've seen trying to use Facebook, Twitter, etc. - there's a huge selection bias with who uses those services, and, even if usage nears 100%, the type of usage will vary between pts by orders of magnitude. This could help increase predictive power, but how much? This is a whole different ballgame than simply using AWS or Google Cloud to store or even process data, which is also of questionable utility (we have some rockin' servers over at LRI, and they're buying more).\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/memory":{"title":"","content":"# Memory\n:memory:\n\n## Recall among chess masters depends on templates\nRelevant cites in my acad.bib : @gobet1996a, @frey1976recall.\n\nHad a discussion about the studies Andersson loves to cite\non chess masters who could play dozens of simultaneous boards,\nbut seem to have no special short-term memory.\n\nThe seminal set of studies was done by Frey and Adesman, published in 1976.\nShows that advanced players can remember pieces on a board only\nif those pieces could have gotten there in the course of a regular chess game,\ni.e. there are meaningful patterns between the pieces.\nWhen they are shown pieces randomly arranged,\ntheir memory is no better than the novice's.\n\nAnother set of later studies\n(and there are tons of other citations to explore)\nby Gobet and Simon in 1996 confirmed the initial findings,\nand further found that even \"chunking\" as an explanation\nis inadequate to explain the mechanism by which\nthe chess masters could remember so many pieces.\nThey suggest instead templates, which I do not fully understand\nbut seem to be what they sound like,\nlarger frameworks that tell the story of how the current state\ncame to be.\n\nNeil Mehta suggested a wonderful exercise of going through the history\nof antibiotics and their development\n(what problems did each successive generation of drugs solve?)\nas a way to build a framework for antibiotics in general.\nThis would help the student deliberately build the framework that the experienced attending developed piece by piece over time,\nand the idea could be extended to one of my favorite subjects of teacher empathy for student learning:\nthe student is trying to build a framework that is second nature for the attending (resident/fellow) from scratch,\nand it can be hard or impossible to remember how hard or impossible that task felt at the time.\nThat is, the learner can be encouraged to build a framework in a specific way,\nand the teacher can be encouraged to think about all the steps that brought them to their current state of knowledge,\nand maybe even to \"think out loud\" when they perform reasoning\n(which can be hard because perhaps they are, appropriately,\nmostly functioning on unconscious reflex that was build over time).\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/olga_botvinnik":{"title":"","content":"Olga Botvinnik's bioinformatics musings (among other things).\nShe has a great\n[post](https://olgabotvinnik.com/blog/teaching-data-cleaning/)\non teaching coding to biologists,\nwhich links to the Software Carpentry's page\n[here](https://carpentries.github.io/instructor-training/).\nIt's basically all of Mehta's stuff, customized for coding, and Botvinnik's post has the feedback she got from students with some nice reflections.\n\nCool ideas include: pair up, and the more experienced student is not allowed to type;\nuse pink and blue post-its to indicate whether a pair is still working or ready to advance (pink = still working).\nShe had some of the same issues I had with different OS in the audience (even at CCLCM!).\nIt's honestly the biggest barrier to starting up.\nMaybe CoLab and the like, but we're trying to make capable researchers, so...\nMaybe whoever sets up the Surfaces could just install miniconda and add it to the PATH!\nThat would probably take care of a lot of the issues.\n\nAnother [gem](https://nbviewer.jupyter.org/gist/olgabot/5357268)\nfrom Olga Botvinnik, using Tufte's ideas in MPL.\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/random_survival_forests":{"title":"","content":"# Random Survival Forests\n:machine_learning:\n\nRandom survival forests (RSFs) function by\nrandomly selecting a bootstrap sample of the data to grow a \"tree.\"\nA randomly selected subset of variables is used\nto find a candidate variable that maximizes the difference\nin survival between subsequent branches,\nand this is repeated until the algorithm runs out\nof branching points and satisfies the requirement that there be\nat least one unique death at the terminal branching points.\n\nSampling assumes independence and samples with replacement.\nPull random samples of the same size by allowing duplicate entries (e.g. in row 1, \"4\" is used twice).\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/learn/want-from-teachers":{"title":"","content":"# What This Millenial Wants From Instructors\n\nIn a word: Context.\n\nI distrust textbooks (they're outdated before they're published),\nand wikis don't fare much better.\nPrimary literature and review literature\nare wonderful, but have their own drawbacks.\n\nA brief word on each of these resources follows, \nthen why I need an instructor to help me put it all together.\n\nTextbooks are meant to give context, \neither for an entire field\nor for a subfield.\nSome textbooks age well, while others do not.\nFor myself as a trainee, the problem is that I do not know\nexactly which parts have aged well,\nand which should be updated.\nWhen I pick up a textbook myself,\nI hope the parts I read will\nbe both accurate and up-to-date, \nbut digging through the new primary literature\nto verify every piece would be a herculean task.\n\nUpToDate is a great wiki-style tool,\nwith good tracing of provenance and upfront reporting of recency,\nand it comes in bite-sized chunks that are easy to use in a busy clinical context -\nbut it also comes in bite-sized chunks,\nand in a busy clinical context clicking through the hyperlinked rabbit holes \nthat would give me the rest of what I need to know is unlikely, and error-prone. \nPrimary literature takes me right to the bottom of the rabbit hole,\nand as a physician-scientist, \nprimary sources make me happy and comfortable - \nbut it \n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/2021-09-16-kennedy-breast-cancer-clinic":{"title":"","content":"# Laura Kennedy, MD PhD\n\n## 2021-09-16 clinic\n\n### 01\n\n- +FHx breast cancer\n- TLH-BSO 2014\n- colo 2018 w TA, next 2021\n- Cr \u003c1\n- LFTs wnl\n- Ca 9.8\n- Hgb 15.3\n- WBC 6.4\n- Plt 295\n\n- mammo b/l w tomo:\n   - prior 2018, wnl?\n   - density category C: heterogenous\n   - R breast 9 o'clock 7.8cm from nipple, +developing asymmetry\n   - BI-RADS 0 (incomplete)\n\n- US b/l\n - scattered fibrocystic changes\n - L axillary lymphadenopathy, ?d/t COVID-19 vax\n - BI-RADS 3 (probably benign, \u003c2%)\n - Note: This score of 3 was assigned because the patient had just had her COVID-19 vaccine, and axillary lymphadenopathy is a normal finding in this setting. It would have been BI-RADS 4 otherwise. From an urgency standpoint, the gap between 3 and 4\n\n- LNBx: L axilla\n  - +ER, +PR, E-cadherin mostly -ve (\u003c5%)\n  - pathologist favors mILC\n\n- MRI breast wwo\n  - L scattered enhancement, no definitive masses\n  - L axillary adenopathy -\u003e subpectoral deep nodes and superior mediastinum\n  - BI-RADS 6 (biopsy-proven cancer)\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/2021-10-01-micu-morning":{"title":"","content":"# Pre-intubation\n\nPresented with O2 sat 81% to the ED, what's next?\n\n## NC\n\nMax flow through standard NC ~6L/min.\n\n~3-4% increase in FiO2 per L, so 2L/min ~= 30% FiO2.\n\nMinute ventilation ~5L/min if assume 10 breaths per minute, \n~500mL tidal volume, \nbut: \n- those are averaged over one minute \n- moment inspiration will exceed that flow rate, \n- the seal isn't perfect,\n\nwe're typically putting O2 on dyspneic people,\nso those assumptions typically do not hold.\n\n## Large-bore NC\n\nBigger tube, up to ~15L/min. Otherwise same as NC.\n\n## Venturi mask\n\nSize of holes determines rough amount of entrainment.\n\n## NRB\n\nOne-way exhale valves, bag w 100% O2.\nStill getting some entrainment, but overall higher O2 delivered.\n\n## HFNC\n\nOptiflow, Airvo, etc.\n\nUp to 60L, 100% FiO2.\nHumidified air, \nmore complete seal on nose piece.\nLess complications from dry air (massive epistaxis),\nless entrainment (though depends on if their mouth is closed).\nAlso provides up to ~5L PEEP.\n\nBlends 100% O2 and medical air to achieve the set FiO2.\n\n[FLORALI trial](https://www.nejm.org/doi/full/10.1056/nejmoa1503326)\n  - intubation rate between HFNC and NIPPV was not different (primary outcome)\n  - ventilator free-days were different (higher in HFNC)\n  - 90d mortality rate better for HFNC than NIPPV\n\n# NIPPV\n\nPressure increase (mean airway pressure),\nmore O2 exchange d/t greater partial pressures of delivered O2\nover more time.\n\n# Invasive ventilation\n\nNext week...\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/2021-10-05-micu-morning":{"title":"","content":"# ARDS\n\nNoncardiogenic pulmonary edema.\n\n## How to confirm \"Noncardiogenic\"?\n\nGold standard would be RHC, \nbut typically defined clinically\n\n## [Berlin Criteria](https://www.mdcalc.com/berlin-criteria-acute-respiratory-distress-syndrome#evidence)\n\nP/F ratio. \n\nSeverity ratings (for prognostication, do not influence tx)\n\n- \u003c300 mild\n- 100-200 moderate\n- \u003c100 severe\n\nPEEP \u003e= 5.\n\nAcute: onset w/in 1wk of insult\n\n## Etiologies\n\nTwo major branches:\nPulmonary vs extrapulmonary.\n\nExtrapulmonary: anything inflammatory (pancreatitis, sepsis)\n\n\n## Mgmt\n\n### Low-tidal volume ventilation: 6mL/kg of ideal body weight\n\n[NEJM 2000](https://www.nejm.org/doi/full/10.1056/nejm200005043421801)\n\nFiner points from this article:\n\n- 6 vs 12\n- plateau pressure targets differed\n- allowances for adjusting tidal volume based on ventilation needs\n- used pressure control, which has led to wider use of this mode\n\n### Conservative fluid mgmt\n\n[NEJM 2006](https://www.nejm.org/doi/full/10.1056/nejmoa062200)\n\n- no mortality difference\n- improvements in ventilator-days and ICU days\n- CVP endpoint less than 4, almost never reached == never cease to diurese\n\n### Proning\n\n[NEJM 2013](https://www.nejm.org/doi/full/10.1056/nejmoa1214103)\n\n- large reported mortality benefit\n- results called into question\n\n### Paralysis\n\n[NEJM 2019](https://www.nejm.org/doi/full/10.1056/nejmoa1901686)\n\n- no mortality benefit\n- still will paralyse patients, but not early as part of routine practice\n\n### Steroids (all-comers)\n\n[Lancet 2020](https://pubmed.ncbi.nlm.nih.gov/32043986/)\n\n- done just prior to COVID-19\n- long enrollment period, very strict enrollment criteria\n- possible improvement in ventilator-days and mortality\n\n### VV Ecmo\n\n[NEJM 2018](https://www.nejm.org/doi/full/10.1056/NEJMoa1800385)\n\n![EOLIA KM Curve](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2018/nejm_2018.378.issue-21/nejmoa1800385/20190311/images/img_medium/nejmoa1800385_f2.jpeg)\n\n- trial ended early for futility, but KM curves did diverge\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/2022-07-07-heme-onc-emergencies":{"title":"","content":"# Hematology and Oncology Emergencies\n\n\n## c/f APL\n\nGen approach:\n\n- page path resident, talk ASAP\n    - if c/f APL by morphology: ATRA 22.5 mg/m2 q12h, FISH AML panel (write \"PML-RARA testing STAT\")\n    - call smear lab to send you a picture, clarify that you are NOT the path resident, this is for academic interest\n- call attg\n- flow cytometry STAT\n- TLS, DIC labs q6-8\n- order PICC\n- start fluids (~125cc/hr)\n- start allopurinol 300mg BID (don't dose reduce for TLS)\n- start hydrea 1g PO q12h\n\n\n## TLS\n\n- best tx is ppx w IVF+allopurinol\n- don't adjust allopurinol, give 300mg BID\n- if uric acid \u003e9, give rasburicase 3mg IV\n- start phos binder prn\n- tx hyperK\n\n\n## DIC\n\nMost guidelines developed for pts w APL\n\n- tfx 10u cryo for fibrinogen \u003c150 (if non-APL consider \u003c100)\n- if INR elev, give vitK 10mg IV\n- plt goal \u003e20k, generally speaking\n\n\n## Hyperleukocytosis\n\n- WBC \u003e100k w 50k blasts generally, but really a clinical dx\n- type of cell matters (really the blasts, leukostasis v rare in e.g. CLL)\n- start hydrea 2g q8h\n- at VUMC: leukapheresis if symptomatic (nephro will do it, admit to MICU)\n- call Holly Casanova for cell collection (even if middle of the night), sign consent next morning\n\n\n## SVC syndrome\n\n- \"Terrible Ts\"\n- managed by not med onc (rad onc, IR, vascular, etc.). \n- but, we can help: rec TLS labs, AFP, bHCG, elevate HOB, consider diuresis, try to get bx (if asymptomatic, can be ok to d/c but schedule bx/PET *before* sending home), start heparin drop if clear thrombus\n- ok to start steroids if needed (e.g. 10mg load then 4q6), airway is more important than bx yield, but do not start empirically\n- also ok to radiate to control hemoptysis, etc. (usu 1-3 fx can control bleeding, regardless of tumor type - do not need tissue first)\n\n\n## Acute Chest Syndrome\n\nNew opacity on CXR and pretty much any thoracic sx, also fever.\n\n- r/o PE w CTA\n- start abx (infx could mimic or precipitate ACS)\n- order Hgb S level (gets drawn in the morning, helps transfusion medicine know how to exchange)\n\n- option 1 (typically less sick, ~2L O2): transfuse blood alone (1-2u RBC, dilutes sickle cells, do not exceed Hgb 10)\n- option 2 (sick): exchange transfusion (transfuse up to a reasonable Hgb, transfusion medicine helps manage - page blood bank path resident, happens in MICU).\n    - Goal Hgb S \u003c30%\n\n\n## Hypercalcemia\n\n- aggressive IVF\n- goal uop 100-150cc/hr\n- zometa 4mg IV over 15 min, no attg approval needed, no renal adjustment. Takes 2-4d for peak effect\n- calcitonin if encephalopathic, needs attg approval, tachyphylaxis at ~48h\n\n\n## Spinal cord compression\n\n- NSGY, rad-onc c/s\n- ok to wait for surgery or at least c/s prior to high dose steroids if sx onset slow\n- consider PSA, SPEP/SLC, CT CAP\n- typical dosing: dex 10mg IV loading then 4mg q6h\n- if prostate cancer: consider degarilex now to prevent spike w leupron\n\n\n## ITP\n\nddx if plt \u003c5:\n\n- platelet clumping\n- HIT (less likely, few HIT pts have plt \u003c5)\n- TTP (less likely)\n- severe DIC\n- alloimmunization in heavily pre-transfused\n\norder:\n\n- citrated plt count\n- smear (r/o clumping, r/o schistocytes/helmet cells/sharp/jagged cells)\n- 1u plt, w 60min post-check (if still \u003c5, dx of ITP)\n- IPF - not harmful to dx, but certain ITP subtypes can attack plt in the marrow so have a low IPF\n\nif dx:\n\n- IVIG 1g/kg q24h x2 (response w/in 24-48h)\n- dex 40mg PO x4d (~10 pills) (better than 1mg/kg pred in pIII trial, blood 2016, CR rate ~50%)\n\n\n## TTP\n\n- admit to MICU\n- if PLEX w be delayed, can give FFP (also has ADAMTS-13)\n- obtain ADAMTS-13 activity level (for dx TTP must be \u003c10%, will be low in most sick pts but not that low), will reflex to inhibitor testing (which can change mgmt)\n- pred 1mg/kg\n- PLEX - talk to nephro fellow\n- ADAMTS-13 testing is fraught, difficult, can be mildly effected by FFP (inhibitor will deactivate ADAMTS-13 in FFP)\n\n## irAE\n\n- always send to ED if at all concerned, need stat imaging, pred\n- pneumonitis: abx, pulm c/s to consider bronchoscopy\n- colitis: depends on sx, # bowel movements\n    - \u003c4BM/day: antidiarrheals at home\n    - 4-6: pred 1mg/kg daily, send stool studies\n    - \u003e6: send to ED, start IV methylpred 1-2mg/kg daily\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/2022-07-08-apl":{"title":"","content":"# APL\n\n- can track fibrinogen bc APL cells secrete proteases, not just a side effect\n- consider gemtuzumab in low risk if ATO contraindicated (QTc prolongation)\n    - gemtuzumab targets CD33\n- consider gemtuzumab in high risk always, particularly if ATO contraindicated\n\nRe ATO and TdP - very low actual incidence, associated w QTc prolongation w electrolyte abnl\n[link to section on TdP in ATO in a book on TdP](https://www.google.com/books/edition/Torsades_de_Pointes/V48mEAAAQBAJ?hl=en\u0026gbpv=1\u0026dq=ato%20tdp\u0026pg=PA286\u0026printsec=frontcover).\nMost guidelines (including in the link) hold ATO when QTc \u003e500ms, resume when \u003c460ms or so.\n\n## Email to Sanjay and Stephen\n\nSent 2022-07-08.\n\nWhen I've discussed TdP risk w cardiologists, they've emphasized that TdP does not typically develop rapidly, but is preceded by bradycardia, and tachycardia is protective. Most of our pts are tachycardic, particularly with concomitant anemia.\n\nI found a nice recent book on TdP, has a section on ATO, mentions that actual incidence is low, and usually in the context of electrolyte abnormalities. Our folks often do have electrolyte abnormalities, particularly if they have renal failure.\n\nAnyway, this is a long way to ask: are there situations where the benefit of ATO in the short term outweigh the risk of TdP at mildly/modestly elevated QTc, e.g. QTc 500-550? I also understand that ATO remains a part of the regimen for quite a while, so may cross into the part of the treatment where the pt is no longer protected by tachycardia, in which case I would worry about TdP at modestly elevated QTc.\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/mitchell-unconscious-bias":{"title":"","content":"# Kevin Mitchell on unconscious bias\n\n- started with intersectionality (he trained as a pharmacist, then physician, is a veteran, from Miami, a husband, a father, a black man, --also big Harry Potter fan)\n\n- \"Code Switching\"\n    - switching language and behavior based on context\n    - learned from mother to purposefully code switch\n    - \"don't be a stereotype...\" (or statistic - non-grad, etc.)\n    - data - [Race, Ethnicity, and NIH Research Awards](https://science.sciencemag.org/content/333/6045/1015) \"2011 Science Mag, Ginther et al. : if top-tier scores, funded equally well, but below upmost echelons people who were black or of Asian decent less likely to be funded\n    - [Racial Disparities in Pain Management of Children With Appendicitis in Emergency Departments](https://jamanetwork.com/journals/jamapediatrics/fullarticle/2441797) (JAMA, Goyal et al.) : children of color less likely to receive analgesia for severe pain\n    - Assimilative techniques: passing (concealing: appear as member of dominant group), temporary passing (projecting), covering (downplay salience)\n\n- Consequences of code switching\n    - imposter syndrome, burden of duality, burnout\n    - gift and curse: street credibility vs professionalism; empathy vs sympathy; pt trust vs colleague comfort\n\n- how to respond to racist/sexist comments (this is a tl;dr of bystander training)\n    - take note\n    - stabilize patient\n    - address the issue\n    - stabilize victim\n\n- other notes:\n    - his \"solutions\" slide was blank when he first started giving this talk, now has several ideas and many angles -- the process of gaining hope and strategy can definitely start with no concrete solutions, but if it's important, keep working at it, get some friends, ideas will come\n    - look into race-based GFR, its history and problems\n\nlast updated: 2020-06-30\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/telehealth-disparities":{"title":"","content":"# telehealth disparities\n\nGetting telehealth set up for providers and patients is difficult.\nThe providers have a rough enough time,\nand there is a near-guarantee that someone is tech-savvy\nenough to figure it out,\nalmost regardless of the complexity of the telehealth system.\nPatients may not have the luxury of technological\nexpertise, or access to it.\n\nThis makes solutions like Zoom's,\nwhere pretty much any browser\ncan substitute for the app proper,\nnot only convenient, but also moral.\n\nMost people have smartphones now,\neven the elderly and poor.\nIf they can get a link,\nand that's enough to get them a telehealth visit,\nthey can get care.\n\nAlso, should data be free in these situations?\nKind of how certain media providers had data waivers on certain carriers\n(e.g. some music app's streaming data wouldn't count against your data usage).\n\nTue 30 Jun 2020 11:44:13 AM CDT\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/medicine/va-vs-vumc":{"title":"","content":"# VA vs VUMC \n(or other academic medical centers)\n\nAt VUMC, the VA is right across a walkway (or vice versa).\nDespite physical proximity, \nthe two institutions have vastly different backend structures.\n\nVA -\u003e US Dept of Veterans Affairs\n\nVUMC -\u003e TN Dept Health (but mostly self monitors)\n\n## residents vs hospitalist teams\nVA: Residents do everything.\nVU: Hospitalist teams do all the \"less educational\" stuff and take care of COVID-19 pts\n\n\n## COVID-19 testing\nVA: Cepheid Rapid Test in-house, Abbott m2000 (gold-standard for PCR-based COVID-19, sent to Lexinton, KY - will call if +)\nVU: in-house PCR\n\n*both PCR-based, nasopharyngeal swabs, varying turn-around times\nTue 30 Jun 2020 11:54:57 AM CDT\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/projects/ai-for-mds-book":{"title":"","content":"# AI for MDs\n\n## Intro\n\n### Why?\n\n- It's happening\n- Data availability\n-\n\n---\n\n### What is AI/ML?\n\n\nAI\n\nTools for doing an intelligent thing (we're not going to get into AGI: while very cool, it's not super practical, and tends to obfuscate the useful stuff --\u003e lead to debates on the nature of humanity, etc.)\n\nExamples of simple AI: thermostats and cruise control.\nA human who would like to maintain a constant speed would\nA) pick the desired speed,\nB) note whether they were currently above or below that speed,\nand C) accelerate up or down to match the desired speed.\nThis is an example of a simple rules-based system,\na series of if-then statements (if above speed X, let off the gas. If below speed X, give it more gas).\nThese are very useful, and you can get a lot of mileage out of them,\nbut if decision-making is complex, then the series of interconnected rules become more complex,\nand increased complexity leads to brittle systems with limited functionality and a high maintenance burden.\n\nML\n\nTools for training a machine to do a thing by giving it examples from which it can learn. We will get into the major categories later, but in brief they are\n\n    - Classification: learn from example whether a thing is an X or a Y. E.g. is this a picture of a hotdog or a shoe? Based on labs, genes, and demographics, does this patient have disease X or disease Y?\n    - Regression: learn from example the quantitative value of a thing based on other data. E.g. based on local property values, square footage, amenities, for how much will this house sell? Based on lab values that are easy to obtain, can we predict another lab value that is difficult to obtain (e.g. bone marrow cellularity, blast percentage).\n    - Unsupervised: from a set of data, find clusters of similar data points. E.g. from a number of whole genome sequences, find patterns of similarity that can be further explored and correlated with phenotype. In an image, locate areas likely to be of interest.\n\n---\n\n### Why you?\n\nData is king, queen, and jester\n\n- [Breast cancer labels cheating](https://www.cs.princeton.edu/picasso/mats/KDDCup08Expl.pdf), [copy of PDF](http://beauhilton.com/assets/npj-dm-readmit.pdf)\n\nThe goal of this competition, organized by Siemens and available on the Kaggle platform\n(which hosts various data science competitions that individuals or teams can freely compete in, often for a cash prize),\nwas to predict the likelihood of cancer from numeric variables derived from preprocessed images.\nAnonymized patient identification numbers were left in the dataset,\nand the winning competitors noticed that these numbers fell in certain ranges in a nonrandom way:\nif a patient ID fell between 100,000 and 500,000, or above 4,000,000, the likelihood of cancer was very low (1-2%),\nbut if the ID was between 0 and 20,000 the likelihood of cancer was much higher (36%).\n\nThe competitors used this knowledge to build a model that performed very well in predicting which patients had cancer,\nbut would not generalize at all to the real world.\nHowever, because the model was a \"black box\" model,\nthe problematic nature of their model would not be readily apparent,\nand serves as a warning that machine learning practitioners\n(and consumers of such technology)\nshould be wary of the data upon which models were built.\n\nThey wrote a lovely paper detailing their findings and warnings.\nWe can imagine much less scrupulous technologists letting their apparent success ride unchallenged.\n\n- [Luke Oakden-Rayner predicting CT manufacturer from scans](https://www.nature.com/articles/s41746-019-0105-1), [copy of PDF](http://beauhilton.com/assets/predict-ct-scanner.pdf)\n\nIn a similar vein, Oakden-Rayner and colleagues used a deep learning model to predict various clinical entities from CT scans.\nParticularly with deep learning models used for image analysis,\nin which there may be millions or billions of parameters used to make the final prediction,\nit can be very difficult to know exactly which features the model is pulling out of the image to make its predictions,\nand in what ways those features interact.\nThe authors of this paper chose to turn things around a bit,\nand give the model the task of predicting the manufacturer of the CT machine,\nwhether the order was stat or not, and other relatively non-clinical curiosities.\n\n- [How to Ask an Actionable Question](https://www.thetalkingmachines.com/episodes/how-ask-actionable-question)\n\n\u003crelisten to this episode\u003e\n\n- [Missing weights](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125114/), [copy of PDF](http://beauhilton.com/assets/npj-dm-readmit.pdf)\n\nOne of our projects sought to predict readmission risk and risk of increased length of stay,\nfrom a number of hospital, demographic, laboratory, and other variables.\nI chose to use a model that was amenable to explanation,\nand could also handle missing values by allowing missingness itself to be a signal\n(this is a confusing statement, but will be more clear with the following example).\nIn both predictive tasks, patients with extreme BMIs had higher predicted likelihood of the adverse outcome,\nand, more unexpectedly, so did patients with *missing* BMIs.\n\nI puzzled on this for some time,\nwondering what a missing BMI could be signalling,\nand then took care of a patient transferred from an outside hospital with a C1-C2 infection with high concern for instability.\nHe was never weighed out of concern that standing him up could precipitate a catastrophic event.\nWhile this particular case is undoubtedly rare,\nperhaps it is not so rare to have patients who are sick enough to never be stood up and put on a scale\n(and I do not trust bed weights enough to include them in any predictive model).\n\nI considered throwing this variable out several times because the results seemed, frankly, weird,\nbut time on the wards rescued it,\nand now I find it emblematic of the communication between data science and clinical work.\nAny hospital administrator looking to improve their prediction of which patients are high-risk\nshould consider looking for oddities such as this,\nespecially if the oddity is readily apparent in the hospital database,\nand exploring anything that seems nonrandom, even if the connection is unclear at first.\n\n- [Labelling heme-path images is hard](https://pubmed.ncbi.nlm.nih.gov/29656215/), [copy of PDF](http://beauhilton.com/assets/heme-path-is-hard.pdf)\n\nI tried to build a deep learning model to predict hematologic malignancy phenotype from ultra-high-resolution scans of bone marrow biopsies.\nI failed miserably.\n\nIt turns out this is a very hard problem.\nApart from considerable technical hurdles\n(most deep learning models are trained on images 255x255 or 512x512 pixels, while these images are on the order of 80,000x90,000 pixels, requiring many decisions regarding pre- and post-processing to make the computation tractable),\nwe quickly realized that our data source was not rich enough and would need an enormous amount of work.\nMany important findings are made on a cell-by-cell basis,\nso we would need to label each cell to build a rich ground truth.\nBut labeling cells is no easy task, and requires experienced hematopathologists,\nwho are busy and expensive.\n\nAfter some time I found I was not alone in realizing these difficulties,\nand a group in Japan was way ahead of me and my team in tackling this problem.\nThis paper explicitly states their end goal,\nto build an automated system to perform diagnoses on hematopathological images,\nand then goes on to explain that they realized they needed more data,\nand that collecting that data would require hematopathologists,\nand that hematopathologists are busy and expensive,\nso they would build a system to make the task of labelling easy and fast.\nAs a part of this, they wanted to evaluate the quality of the labels they were going to obtain,\nand so performed a study to quantify agreement between hematopathologists for a select number of cellular entities and quantities.\nThey found consensus in some things, when they were obvious,\nbut nonconsensus in non-obvious things.\n\nHow, then, to build a model to automate part of a hematopathologist's job\n(and hence to make advanced hematopathology available in less resource-rich settings),\nif ground truth is so difficult to obtain, and shaky?\nThis basic problem is repeated throughout machine learning in medicine,\nfrom improperly or incompletely labeled radiographs\nto chart-based diagnoses based on billing concerns more than clinical realities.\nWe need experienced clinicians to generate, evaluate, and mobilize data,\nand there is not (and, I argue, will never be) a substitute for direct experience with real patients\n(or, in the cases of pathology and radiology, the tissues and images of real patients, and consultation with the clinicians who ordered the studies).\n\n---\n\n### How to learn\n\nThere is an ever-growing number of learning resources available for the would-be data scientist.\nThese range from in-person degrees at prestigious institutions,\nto online courses and certifications,\nto books,\nblog posts,\nand code examples that themselves range from the\nline-by-line hands-on approach\nto the highly cerebral and theoretic.\n\nWhich resources you choose to use will depend largely on your goals.\n\nIf you want to be a theoretician,\nyou may start from the ground up\nand study the core mathematics and computer science.\n\nIf you want to be an engineer,\nthat is, one who applies the tools to real world problems,\nyou may prefer a hands-on approach at first,\nand dip into the theory as needed to troubleshoot deeper issues.\n\nYou may want to be neither of these,\nbut instead your goal is to be a responsible citizen\nwithin your medical field,\nwith enough understanding to critique the\nacademic articles and,\nperhaps more importantly,\nsoftware tools employed within your practice and institution.\nThis may be analogous to the way and reasons we learn\nstatistics in medical school,\nnot to become statisticians,\nbut to know how to speak with statisticians,\nhow to collaborate,\nhow to understand what we read,\nand spot poor practice\nor misleading claims.\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/teach/2018_job_roles_of_2025_educator":{"title":"","content":"# Job Roles of the 2025 Medical Educator\n:teach:\n\n- Futurist concept of *hard trends* (the cite, sadly, is not Kevin Kelly)\n\t- measurable predictions\n- Outsourcing\n- WTH do they mean by \"big data\"? In what world will there be enough data streams of sufficient size coming from med students to justify this terminology?\n\n## Roles\n\n- Diagnostic Assessor\n\t- Even if the use if the term \"big data\" is misguided, the idea is well-taken - data will be generated, some of it useful for predictive modeling. Can we collect data that can lead to meaningful early interventions, etc.?\n\n- Content Curator\n\t- situatedness (the smoke filled back room, the history of the thing)\n\t- levels of curation\n\t-\n\n\n- Technology Adopter\n\t- maybe KK's \"Amish Hackers\" article would be good addition here\n\t- I don't know if \"must be early adopters\" is right at all\n\t-\n\n- Learner-Centered Navigator and Professional Coach\n\t- another aspect of this may be that as medical knowledge expands, medical education shrinks to cover the essentials (whatever those are deemed to be) and allow self-directed exploration of deeper topics in whichever field. The coach would help the student discover and direct deeper interests, and connect them with resources (human and technological)\n\t-\n\n- Clinician Role Model\n\t- yup, on board with this one\n\t- tho I don't think each clinician has to model everything perfectly, nor could they\n\n- Learning Environment Designer, Engineer, Architect, and Implementer\n\t- kind of ties much of the above together - know what the students need (has assessed the state), what content is already available, which technologies may  or may not be useful to fill the gap. May or may not have coach and/or role model roles as well.\n\t-\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/teach/2018_learning_sci_immersive_vr":{"title":"","content":"# VR vs not-VR for learning\n:teach:\n\n## multimedia learning\n- learn from words and pictures\n\n## coherence principle\n- people learn better when extraneous words are excluded\n- not just words, but details (e.g. cartoons can work better than photographs in certain settings)\n- what is extraneous depends on context and learning goal\n\n## segmenting principle\n- people learn better in user-directed segments\n\n## generative learning theory\n- selecting, organizing, integrating\n\n## add a feature\n- have people step in and out of the game to process (e.g. give them a worksheet to fill out as they play the game)\n\n\n# some thoughts\n- autotune\n- apples vs apples (brought up repeatedly by the authors)\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/teach/cognitive_load":{"title":"","content":"# types of cognitive load\n:teaching:\n\nThree types of cognitive load:\n- Germane\n- Intrinsic\n- Extraneous\n\nRichard Mayer - 9 Strategies for cognitive load\n\n\n\n| Cognitive Processing | Description                                                   | Instruction Design Goal |\n|----------------------|---------------------------------------------------------------|-------------------------|\n| Extraneous           | Not related to instructional goal                             | Reduce                  |\n| Essential            | Caused by complexity of material (unavoidable)                | Manage                  |\n| Generative           | Aimed at making sense of material, caused by learner's effort | Foster                  |\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/teach/ed_tech":{"title":"","content":"# educational_technology\n:teach:\n\n## Don Norman on video games\n\nBeautiful thoughts from Don Norman.\n\nHe begins by talking about how video games can engage\neven the most unruly and distractable learner,\nand how the same things that keep the gamer involved\ncan be employed to keep the learner involved\n(for they are one and the same).\n\nHis list of what tech can do is a masterclass in itself.\n\nTech can:\n- motivate\n- make visible what is otherwise not\n- allow for the study of the complex\n- take care of the drudgery [and thus]\n- allow for concentration on the profound\n- **be patient**\n- give endless rewards and challenges\n- continually engage the mind\n- move the teacher into the roles of guide, mentor, and **fellow explorer of knowledge**\n\nThe idea of tech as patient\n(if you build it right,\nit will *let* you try over and over again,\nuntil you get it right or decide to move on)\nis a refreshing reversal of the way I often think about it:\nI *had* to keep on trying over and over again,\nuntil I finally got it right. (This in relation to bugs).\nBut it could be:\nI *got* to keep on trying over and over again, until I finally got it right.\n(This in relation to hard concepts that take a while to sink in).\nAnd really, as I've programmed more and more, \"bugs\" and \"hard concepts\" are one and the same.\nThough of course bugs due to poor software design do exist,\nI have learned it is more productive to first (and second and third)\nquestion my grasp of the concept, before jumping to an accusation or\nintimation of ill will or laziness on the part of the designer.\n\n\nhttps://jnd.org/learning_from_the_success_of_computer_games/\n\n---\n\n\u003e Technology is not the answer to the ailments of education. All of us succeeded in an educational system that was mainly empty of technology. But technology can help. It can motivate, it can make visible what is otherwise not, allow for the study of the complex, taking care of the drudgery and allowing for concentration on the profound. It can be patient. It can give endless rewards and challenges. It continually engages the mind. And it provides a new, more rewarding role for the teacher as a guide, mentor, and fellow explorer of knowledge.\n\n\u003e The proper technology, coupled with proper teachers, can indeed transform. Learning is through doing, or though what I once proclaimed was a state of \"critical confusion.\" People learn best, I argued, when challenged -- just enough to be confused, just enough to be motivated to search, to struggle, and to achieve.\n\n\u003e We learn not by having our heads filled with the great thoughts and ideas of others, but by constructing them within our own conceptual structures. But this construction works best when the scenario is rigged so as to lead us to the ideas, to force us to confront them and understand them. This is what the successful game designer does. This is what the successful educator must do.\n\n\u003e Technology is not the answer, but proper technology coupled with informed pedagogy, coupled with teachers that are coaches, guides and mentors, can lead the way.\n\n---\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/teach/introducing_ml":{"title":"","content":"# Teaching ML\n:teach:\n\n## Introduction\n\nArtificial intelligence is the science of getting machines to do things that intelligent beings do.\n*draw circle with AI*.\nMachine learning is an approach to\n\n\n![dl_ml_venn](/images/dl_ml_venn.jpg)\n\nhttps://arxiv.org/pdf/1206.5538.pdf\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/teach/introducing_python":{"title":"","content":"# colab\n\nColab is great.\n\n\n# twitter\n\nconsumer_key = 'ENTER_YOUR_CONSUMER_KEY'\nconsumer_secret = 'ENTER_YOUR_CONSUMER_SECRET'\naccess_token = 'ENTER_YOUR_ACCESS_TOKEN'\naccess_token_secret = 'ENTER_YOUR_ACCESS_TOKEN'\n\n{ezNwnILv8rPXid5shxCXUi8t4} (API key)\n{tQLPLzQ41irSIveROjtxkxibekYEoGtX38xO4oKAkvTBniRJWk} (API secret key)\n\n{788048438-oDRCMjkwYiew69HTSYk5rTKeIbpYedOqipjIaXYG} (Access token)\n{PYLcdWuI7kgMsVqASIdGEDOD4bOhy28oxAZRA3RZpbEFc} (Access token secret)\nRead and write (Access level)\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/SSH_in_git":{"title":"","content":"# ssh_in_git\n:git:ssh:\n\nEntering one's passphrase/password every time a commit is pushed is annoying. Github has a nice guide for setting up SSH access and SSH-agent: https://help.github.com/en/articles/connecting-to-github-with-ssh .\n\nI need to figure out how to make it automatically sign in to SSH-agent when I unlock the computer.\n\nI think I got it working with these instructions: https://unix.stackexchange.com/questions/339840/how-to-start-and-use-ssh-agent-as-systemd-service\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/blarbs":{"title":"","content":"# blarbs\nI decided to fork Luke Smith's LARBS setup.\nI was hesitant at first, mostly because they are still making pretty frequent updates, and I don't want to go through the trouble of updating mine to match theirs, plus my own edits.\nAfter a while I realized that there's really nothing super broken in LARBS as it is, so I might as well get on with forking it before my X220 arrives.\nThere's also a bunch of stuff I will be removing (e.g. all the special character bindings in the .vimrc). I want to keep some of the rad things, like leader-c for compiling all the things, and the overall workflow and aesthetic, but take things apart, understand how they work, and optimize them for my own stuff (i.e. I do a lot of Python programming, and use Jekyll rather than Luke's minimalist wubsite thing).\n\nBTW, Serge Gainsbourg is a hoot.\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/convert_many_pdfs_to_jpg":{"title":"","content":"# Convert Many PDFs Into JPG\n:image_processing:\n\n    for f in *.pdf; do convert -verbose -density 150 -trim \"$f\" -quality 100 -flatten -sharpen 0x1.0 \"${f%pdf}jpg\" ; done\n\nThis gives pretty nice rendering of text and images, though it isn't perfect. It's the best solution I've found so far.\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/convert_tex_table_to_csv":{"title":"","content":"# Convert TeX table into csv(ish)\n:latex:\n\n    cat table2detex.tex | sed 's/\\\\%/percent/g' | detex | sed 's/\u0026/;/g' | sed 's/percent/%/g' \u003e tab2file.txt\n\nI copy the table into a new file, then convert the % symbols so detex doesn't get rid of them, then detex to get rid of the LaTeX markup, then convert the \u0026 into whichever delimiter you want (;, pipe, tab, etc.), then reconvert the percents back into symbols, and output to a .txt file. It's important to NOT use a csv if you are going to open in Excel, because it will assume commas are the delimiter. If you use a text file, it will ask you what you want the delimiter to be.\n\nThe next step here would be to insert a special commented-out sequence before and after all the LaTeX tables so you can select that portion with a sed/grep/awk command and not have to make a new TeX file.\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/doc_formatting":{"title":"","content":"# doc_formatting\n:rmarkdown:\n\n# Bibliography formatting\nCSL files specify the format for bibliographies, and also in-text citations.\nIn order to switch the citation style for a given project, just switch the CSL file.\nThis can be done in two main ways in RMarkdown: download the CSL file to your machine and tell the YAML header where it is (`csl: path/to/nejm.csl`) or specify a url (`csl: https://raw.githubusercontent.com/citation-style-language/styles/61b34393eb1b7db87603b537ebd61e0936565e99/the-new-england-journal-of-medicine.csl ).\nBoth have advantages: the first means you don't have to be online for your doc to compile, and the second means you don't have to clutter up your directory or worry as much about the format changing without you knowing it.\nIn my experience, most journals actually aren't as particular as they tend to claim, so as long as the changes aren't major nobody is likely to notice you aren't using the very newest version of their citation requirements.\n\n# Bibliography location\nIf left to its own devices, RMD files will throw the references section at the very end.\nFor most journals, you will want the figures and tables after the references.\nThe easiest way to change the location of the references section is to add in this html tag:\n`\u003cdiv id=\"refs\"\u003e\u003c/div\u003e`\nThis will pull in the references section wherever you put the tag. Easy-peasy.\nI also love that RMD/MD accepts arbitrary pieces of html (though I do not know the limits of this approach).\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/latex_groff_pro_typographers":{"title":"","content":"# troff_vs_tex_vs_pro_typographers\n\nThis article and the discussion below is one of the best examples of what the Internet is for: http://web.archive.org/web/20150417042513/http://typophile.com/node/43702 .\nThe author asks why TeX and troff (etc.) haven't more traction outside of the sciences,\nand gets a discussion about the strengths and weaknesses of these software, and of WYSIWYG tools (a la InDesign).\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/ncmpcpp":{"title":"","content":"Getting the visualizer to work in ncmpcpp was a pain, followed the instructions on the\n[Arch wiki](https://wiki.archlinux.org/index.php/Ncmpcpp)\nand made the /etc/mpd.conf and ~/.config/mpd/mpd.conf match (at least the parts shown in the wiki , I left everything else alone),\nand copied the stuff from the Arch wiki into the ~/.config/ncmpcpp/config file,\nmaking sure all the other instances of those settings were commented out.\n\nBTW, I really like that the ncmpcpp config file is also the manual,\nbut it makes scrolling through it a bit tedious, so I'm plus/minus on that way of doing things.\n\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/time":{"title":"","content":"# time\n:linux_setup:\n\nI noticed at one point that some websites were getting angry that my time didn't match theirs. It seems the easiest way to fix this is to install ntp (Network Time Protocol), then install networkmanager-dispatcher-ntpd and reboot. https://wiki.archlinux.org/index.php/Network_Time_Protocol_daemon#Start_ntpd_on_network_connection\n\nIt may also be useful here to note the NetworkManager dispatcher script found on https://wiki.archlinux.org/index.php/System_time#Update_timezone_every_time_NetworkManager_connects_to_a_network . It will automatically switch the timezone appropriately whenever you connect to a network.\n\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/vimrc":{"title":"","content":":vim:\n\n# sudo command for when you forget\nI often forget to open files in sudo when it's needed,\nand don't notice until I've done a bunch of work\nthat I would prefer not to lose.\nThis is a great couple of lines to add, from\n[Stack Overflow](https://stackoverflow.com/questions/2600783)\n\n    cmap w!! w !sudo tee \u003e /dev/null %\n\nThis teaches a few things, as outlined on the SO post:\n% means \"current file\"\nWhen you call :w in Vim, it actually isn't modifying your file,\nit is rather sending the current buffer to a file with the name you specify,\nwhich is the current file if you pass no extra commands to :w, but could be anything\n(e.g. :w biji2.mom).\nIn this case, we send it to `tee`, which sends to the specified file\n(`%`) as well as the standard output,\nwhich we redirect to `/dev/null` so it doesn't clutter up the stdout.\nVim is often not sudo-accessible, but tee is, so we bypass the problem I usually have.\n\n# SpellBad and friends\n\nUseful commands:\n- leader + o to turn on spellcheck (Luke Smith's binding, nice).\n- ]s to go to the next misspelled word, [s to go to the previous.\n- zg to add a word to the internal dictionary.\n\nAdd the following into your .vimrc to get more sane orthographic highlighting:\n\n    hi clear SpellBad\n    hi clear SpellLocal\n    hi clear SpellCap\n    hi clear SpellRare\n    hi SpellBad ctermfg=red\n    hi SpellLocal ctermfg=green\n    hi SpellCap ctermfg=yellow\n    hi SpellRare ctermfg=green\n\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/vimwiki_in_git":{"title":"","content":"# vimwiki_in_git\n:git:vimwiki:\n\n# Setup\nIt took a bit of work to get this working, but I think we're there now. EDIT: I abandoned the .wiki version in favor of vanilla .git . It's much easier, and I can use folders.\n\nSteps to reproduce:\n\n- Make a new repo (this is probably optional, could have just used my \"life\" repo, but repos are free. :)\n- Get GitHub Pro with my student ID (wiki's are a Pro-only feature)\n- Navigate to the \"wiki\" tab on the website\n- Click into any of the pages, then \"clone this wiki locally\" (will have a link something like https://github.com/cbeauhilton/vimwiki.wiki.git - I converted this to an SSH format so I could use my key: git@github.com:/cbeauhilton/vimwiki.wiki.git )\n- Git clone git@github.com:/cbeauhilton/vimwiki.wiki.git\n- Either start writing from here, or copy in the old vimwiki contents (e.g. cp -a vimwiki/. vimwiki.wiki/ )\n- Git add/commit/push\n- Check it out on GitHub!\n\nThe tutorial found here is very good, and I used most of its steps, subbing in GitHub for GitLab: https://opensource.com/article/18/6/vimwiki-gitlab-notes\n\n# Organization\nI tried to put things into folders to make the directory cleaner, but that borked the compatibility with GitHub (it could probably be worked out, but...). It seems that the best way to keep this organized and compatible with GH is to keep the structure flat, then make the index.md collapsible and well organized visually. On GH, the \"pages\" page will be essentially useless, but accessing the index will show a pretty and well-organized page. If I decide to sidestep GH at some point, I could pretty easily go back to folders.\n\nEDIT: Using the .wiki style ended up being a pain, and the links in a normal GitHub repo work just fine.\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/archive/tech/working_with_python":{"title":"","content":"# working_with_python\n:rmarkdown:\n\n# Enabling Python in RMD\nInstall the reticulate package.\nEnable it as below.\nIt's the bee's knees.\n\n# Conda environments\nCall an R command `use_condaenv(\"env_name\")` like so:\n\n```{r, echo=FALSE}\nlibrary(reticulate)\nuse_condaenv(\"lgb_shap\")\n```\n\n# Matplotlib plots\nThey work. Make sure to call `plt.tight_layout()` so the formatting is pretty.\n\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/by-the-numbers":{"title":"cancer by the numbers","content":"\n# cancer therapies, by the numbers\n- a long list of numbers relative to cancer therapies, to be memorized as thought aids\n\n```dataview\nTABLE \nbtn, btni\nFROM \"\"\nWHERE btn\n\n```\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/chemo-emergencies":{"title":"chemo emergencies","content":"\n# chemo emergencies/urgencies/toxicity overview\n\n# platinum agents\n\n\n# [[taxane]] hypersensitivity\n- double check chemo plans, also triple remind the pts (home-based regimens, they will need to remember to take the steroids, etc.)\n# cetuximab\n- anaphylaxis most common in areas w Lone star tick bites, allergy to red meat\n# [[rituximab]]\n- infusion reaction, different than hypersensitivity rxn (not IgE mediated)\n- prevention: premed APAP + antihistamine\n- slow titration of infusion rate\n- if rxn occurs (usu anaphylactoid, usu w/in 30-120min):\n\t- stop or slow rate (50%), depending on severity\n\t- if stopped, wait a bit, give steroids (dealer's choice, but IV hydrocortisone is pretty standard), and whatever else you think is indicated (e.g. meperidine), and restart at 50% of prior rate, increase every 30min or so\n# [[daratumumab]]\n- hypersensitivity\n- 1st infusion, occurs in up to 50% of pts on IV therapy (~13% of SQ)\n\n# [[obinutuzumab]]\n- reaction *and* hypersensitivity\n\n# [[gemtuzumab ozogamicin]]\n- hypersensitivity\n- same deal: stop infusion, give steroids, resume at 50% when sx resolved\n\n# [[5-FU]] or [[capecitabine]]\n- homozygotes for dihydropyrimidine dehydrogenase (DPD) mutation, or thymidylate synthase mutation. \n- severe GI, hematologic, cardiac, neurologic toxicities\n- antidote: uridine triacetate, direct antagonist (removes benefit of 5-FU, also reduces)\n- 615-343-9211 chemo pharmacist on-call\n\n# HD-[[MTX]]\n- protocolized, antidote is glucarpidase (Voraxaze)\n\n# [[ifosfamide]] encephalopathy\n- confusion (80%), hallucination (30%), incontinence/muscle twitching. Can look comatose.\n- biggest risk: elevated creatinine\n- tx: methylene blue (MAO pathway -\u003e chloracetaldehyde, ifos metabolite thought to be the offending agent. unknown if methylene blue actually helps)\n# [[gemcitabine]]\n- \"gem flu\": w/in 24-48h after infusion: 45% fever (usually low, but can be very high), 20% flu-like sx\n- gemcitabine-related TMA: mimics TTP. can occur at any time, v rare. tx w holding drug, consider eculizumab.\n\n# [[everolimus]]\n- SWISH study gave dexamethasone swish and spit, helped reduce incidence of stomatitis\n\n# when ok to hold drugs\n- most oral agents are ok to hold, particularly if the goal of tx is palliative\n\n# irritant vs vesicant\n- irritant: PIV\n- vesicant: central line (port, PICC), but not absolute rule\n\n# when to get a port?\n- infusional chemo\n- vesicant chemo w high rate of rxn: e.g. anthracycline, higher dose cisplatin, most breast cancer regimens, aggressive leukemia/lymphoma regimens\n- e.g. TCHP\n- if had PICC for their first cycle, try to get a port for the next cycle (or if you have time before the first cycle and they'll need a PICC eventually, can get a port instead)\n\n# pump malfunctions\n## neulasta on-body injector (OBI)\n- most important question: is the med reservoir empty?\n- if pump is messed up, get them an Extended Hours Clinic appt\n- if messed up w/in 72h of chemo and neulasta not given, ok to place one-time order for SQ pegfilgrastim and schedule infusion appt\n\n## [[5-FU]]\n- call infusystem: 1-800-315-3287\n## [[blinatumumab]]\n- call attg and infusystem\n- ","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/chemo-overview":{"title":"chemo overview","content":"\n# chemotherapy overview\n\n## [[anthracyclines]]\n- naturally occuring (\"bicin\", \"mycin\")\n- ~8 proposed MOA\n- limited by:\n\t- myelosuppression\n\t- cardiotoxicity (lifetime limits on doses)\n\n[[dirty data]], [[adverse effects]] [[risk mitigation]]: often the total lifetime dose of [[anthracyclines]] is unknown, e.g. they had treatment elsewhere and records are sparse. Try to figure out the regimen they got, and use the highest dose of anthracycline in that regimen as if they got the full planned dose.\n\n\n\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/commonplace_book":{"title":"commonplace book","content":"\n\nThe [[Commonplace Book]] is not so much \"commonplace\" as it is a \"common place\" for gathering ideas.\n\nFrom [[loci communes]] of antiquity (maybe related to the memory palace?),\nto the Medieval [[florilegium]], or \"gathering of flowers,\"\nwhich were scrapbooks of religious themes,\nand on around to Ryan Holiday's shoebox of 3x5 notecards,\nit is essentially a homemade thought bank from which to withdraw and deviously employ someone else's hard-earned insights.\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/css_custom_fonts":{"title":"using custom fonts in a web page","content":"\n# fonts\n\n2022 update: now I just use system fonts. Cf. \u003chttps://endtimes.dev/why-your-website-should-be-under-14kb-in-size/\u003e\n\n---\n\nTL;DR:\n\n+ add your own fonts by referring to them in style.css and making sure they exist\n+ if the font is available on Google Fonts (and mine was), go to \u003chttps://google-webfonts-helper.herokuapp.com/fonts/ibm-plex-serif\u003e\n+ download the woff and woff2 files for the fonts you want\n+ put these in a fonts directory in your website\n+ link to them in your css\n+ add the line `font-display: swap;` to `@font-face` to avoid invisible text during loading\n+ add caching to make subsequent loads faster - `relayd(8)`\n\n---\n\nIn making my website more minimal, but still my own, font choice seemed a good place to start. I love IBM Plex, and use it everywhere. I wanted to use it on my website, but was a little confused as to how to make it happen without needing a dynamic link to some other website to source the font (e.g. IBM Plex has been added to Google Fonts, so an easy way to get it on my website is to link to their resource). The problem with this is that it needs to query their website every time a new visitor comes to mine, and that is less efficient and makes me dependent on Google. (Btw, the most suckless thing to do would be to just use the user's system monospaced font with `font-family:monospace` -- that's exactly what suckless.org does -- but this is a *personal* blog, dammit, and I'm going to strike a balance between minimalism and personality -- call it essentialism, maybe)\n\nI've been using Derek Sivers' website design as inspiration in a few areas (\u003chttps://sivers.org/style.css\u003e),\nand noticed that his stylesheet has a bunch of gobbledygook at the beginning that looked like a base64-encoded file,\ndumped right in his plaintext CSS.\nThat is exactly what it is,\na font called \"valkyrie_c4,\"\nthat is loaded every time his style.css is loaded.\nInspired by that, but wanting to make my style.css a little more readable,\nI poked around and found `google-webfonts-helper`,\na very cool herokuapp that lets you extract Google Fonts into various formats,\nincluding the woff/woff2 format Derek is using.\n(\u003chttps://google-webfonts-helper.herokuapp.com/fonts/ibm-plex-serif\u003e)\nIt also gives you a code snippet to include in your css,\nwhich does the same thing Derek's base64 encoding does but puts the font source code in a different file,\nmaking the css file more readable.\nIt also gives the advantage that after the font is loaded the first time on a user's browser, it can be cached,\nmaking subsequent loads of your already smoking fast static site even faster\n(I currently have a Google PageSpeed of 99/100,\nwith the point docked for a few things including not yet having a font-display css feature,\nand not having a caching policy,\nwhich I used to think was a good idea but might just add complexity I don't really need since my load times are fast without it\n- \u003chttps://ifconfig.se/simple-web-stack.html\u003e).\n\nGoogle PageSpeed gives a few tips,\nand I got mine to 100/100 by just adding `font-display: swap;` to the `@font-face` sections of my style.css.\nThis lets the browser use an existing font while the other font is loaded. \u003chttps://web.dev/font-display/\u003e\n\nAdding caching takes a little more work on OpenBSD with httpd, because httpd doesn't do caching.\nI love that OpenBSD fights feature creep! Instead, use `relayd(8)`.\n\nSome resources on `relayd(8)` and caching:\n\n- \u003chttps://github.com/reyk/httpd/wiki/Using-relayd-to-add-Cache-Control-headers-to-httpd-traffic\u003e\n- \u003chttps://parksdigital.com/httpd-and-relayd-on-openbsd.html\u003e\n- \u003chttps://ifconfig.se/simple-web-stack.html\u003e\n- \u003chttps://web.dev/uses-long-cache-ttl\u003e\n\nSun 28 Jun 2020 06:36:52 AM CDT\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/deep_work_by_cal_newport":{"title":"Deep Work by Cal Newport","content":"\n# Deep Work by Cal Newport\n\nOne of the chief things which my typical man\nhas to learn is that the mental faculties\nare capable of a continuous hard activity;\nthey do not tire like an arm or a leg.\nAll they want is change---not rest, except in sleep.\n\n* Arnold Bennett, \"How to Live on 24 Hours a Day, 1910\"\n* p. 214\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/desert_fathers":{"title":"Desert Fathers","content":"\n\n# On the individuality of worship\n\nA brother asked one of the elders: What good thing shall I do, and have life thereby? The old man replied: God alone knows what is good. However, I have heard it said that someone inquired of Father Abbot Nisteros the great,the friend of Abbot Anthony, asking: What good work shall I do? and that he replied: Not all works are alike. For Scripture says that Abraham was hospitable and God was with him. Elias loved solitary prayer, and God was with him. And David was humble, and God was with him. Therefore, whatever you see your soul to desire according to God, do that thing, and you shall keep your heart safe.\n\nTue 28 Jan 2020 12:15:59 PM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/design_of_everyday_things_don_norman":{"title":"The Design of Everyday Things by Don Norman","content":"\n# The [[Design of Everyday Things]] by [[Don Norman]]\n\nA conceptual model is an explanation,\nusually highly simplified, of how something works.\nIt doesn't have to be complete or even accurate as long as it is useful.\nSimplified models are valuable only as long as the assumptions that support them hold true.\n\n* pp. 25-26\n\nPeople don't want to buy a quarter-inch drill. They want a quarter-inch hole!\n\n* pp. 33-34\n* Theodore Levitt\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/dirty-data":{"title":"dirty data","content":"\n# dirty data\n\nAll data are dirty, but some are useful.","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/empiric-antibiotics":{"title":"empiric antibiotics","content":"\n# Skin/soft tissue\n\n@eileen_hasse\n\n## PO options\n- staph:\n\t-  doxy\n\t-  linezolid\n\t-  clinda (diarrhea, often high levels of resistance)\n\t-  bactrim\n- strep: \n\t- keflex (true q6h dosing)\n\t- cefadroxil (BID)\n\t- amoxicillin\n\t- augmentin (\"amoxicillin plus diarrhea\")\n\n\n# UTI\nDon't treat UA w/o sx, unless pregnant or prior to urologic procedure. Symptomatic sterile pyuria: can challenge with abx or wait and watch.\n## PO options\n- nitrofurantoin\n- bactrim\n- augmentin\n- cefdinir (3rd gen)\n- fosfomycin (one time dose, covers ESBL, expensive)\n- don't need a fluoroquinolone unless pyelo o/p tx (e.g. young female who is doing ok w PO intake)\n\n# PNA\n- strep pneumo, H flu, moraxella, legionella, mycoplasma, staph, PsA\n## PO options\n- azithromycin + something\n\t- amox\n\t- augmentin\n- FQ\n\n## IV options\n- CAP: azithromycin + CTX\n- HAP: vanc + cefe, vanc + zosyn\n- think about MRSA nares, though can have nares -ve/trachea +ve\n\n# Meningitis\n- n meningitidis, strep pneumo (MCC), H flu, listeria (\u003e50yo, immunocompromised)\n- HSV\n## IV options\n- vanc (s pneumo is sometimes resistant to CTX, not for MRSA)\n- CTX\n- +/- ampicillin (listeria)\n- +/- acyclovir (HSV)\n- dexamethasone\n\n## course\n7-21 days, depending on the bug","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/equations-in-oncology":{"title":"equations in oncology","content":"\n# equations in oncology\n- Standard Dose Intensity (SDI, amount rx) vs Delivered Dose Intensity (DDI, amount actually given), goal typically DDI/SDI \u003e85% for curative therapies","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/essentialism_greg_mckeown":{"title":"Essentialism by Greg McKeown","content":"\n# Essentialism by Greg McKeown\n\nThe crime which bankrupts men and states is that of job-work;\ndeclining from your main design to serve a turn here or there.\n\n* p.124\n* Ralph Waldo Emerson\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.416611565Z","tags":null},"/notes/finite_infinite_games_james_p_carse":{"title":"Finite and Infinite Games by James P. Carse","content":"\n\nIt is an invariable principle of all play,\nfinite and infinite,\nthat whoever plays, plays freely.\nWhoever _must_ play, cannot _play_.\n\n* p. 56\n\n\n_Note_:\nThis is reason enough for removing \"necessity\"\nby whatever means necessary---the idea of need,\nfinancial need (Money Mustache),\ncaloric need (fasting),\neven moral need (skillful means, _Veni, Sancte Spiritus_).\n\n---\n\nTherefore, poets do not \"fit\" into society,\nnot because a place is denied them\nbut because they do not take their \"places\" seriously.\nThey openly see its roles as theatrical,\nits styles as poses, its clothing costumes,\nits rules conventional, its crises arranged,\nits conflicts performed, and its metaphysics ideological.\n\n* p. 56\n\n---\n\nSociety is... an attempt to forget\nthat we have willfully forgotten\nour decision to enter this or that contest and to continue in it.\n\n* p. 41\n\n---\n\nThe joyfulness of infinite play,\nits laughter,\nlies in learning to start something we cannot finish.\n\n* Section 24\n\n---\n\nDeath in life can be regarded as an achievement,\nthe result of a spiritual discipline, say,\nintended to extinguish all traces of struggle with the world,\na liberation from the need for any title whatsoever.\n\"Die before ye die,\" declare the Sufi mystics.\n\n* Section 20\n\n_Note_: Which Sufi(s) say this?\nAlso, I frequently entertain the idea of not hanging my degree certificates on the wall of my office.\n\n---\n\nTue 30 Jun 2020 10:50:01 AM CDT\n","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/notes/hemepath-capstone-2022-07-12":{"title":"hemepath-capstone-2022-07-12","content":"\n# hematopathology capstone\n\n- \u003e20% other == high concern for malig, but no guaranteed results (e.g. mono can have tons of \"other\" cells)\n- with karyotype reporting: are all results reported out, or only sig results? E.g. is the # cells always reported, are all translocations reported, are the q reported always or only for known important loci?\n- [[data science opportunities]]: FISH reports do not have a standardized order for reporting (e.g. the one in the example happened to be in the order of the panels). Do current scraping efforts go line-by-line and do specific selection? It would be nice to structure this stuff automatically, easier to load into proper db for analysis.\n- in clinical settings, outside of cell harvesting for SCT, once a cell has been through a flow cytometer it is no longer used for anything. (in research settings, cells are recovered on the other side of the flow cytometer all the time)\n- if not in CR, occ still send PCR to see if the targeted therapy has knocked down the clone in particular and another clone has arisen (as of yet, unlikely to change mgmt). I could imagine, if multiple targeted agents for a certain class of mutation exist, PCR could help fine tune things (but it seems we're a while off from not needing cytotoxic therapies - I wonder about the whole agricultural analogy w targeted suppression of goofy mutants and wildtype)\n- VAF vs AR\n\t- allelic ratio == number of mutants against number of wild type (a bit older tech)\n\t- variant allele frequency == number of mutants against total runs, validate against 4% typically (certain targets can validate down to 1%)\n\t- not clear if one approach is superior, guidelines are in flux\n- [[EHR design]]: linking meds and labs (e.g. if ATRA is ordered, should have an aggressive prompt to order the proper FISH study)\n- why do infections cause monotypy/monoclonality?\n\t- monotypic/monoclonal populations of white cells may arise in infections or other stressors bc of selection for most effective tools (I don't know about any data for this, but sounds reasonable)\n- for stat cases, talk w the hemepath fellows","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/notes/icon":{"title":"favicons","content":"\n# favicon\n\n---\n\n2022 update: I now use SVG emoji. View the page source to see.\n\n---\n\nI need an icon, favicon, etc. I have one from my old website, but it might be nice to migrate to a newer, simpler one.\nI prefer SVG for everything if possible.\n\n\nThe Sara Soueidan website [here](https://www.sarasoueidan.com/blog/icon-fonts-to-svg/) seems to have it figured out.\n\nShe also links to this, which explains [why SVG is winner winner](https://css-tricks.com/icon-fonts-vs-svg/).\n\nTue 23 Jun 2020 08:40:45 AM CDT\n","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/notes/misc":{"title":"miscellaneous quotes","content":"\n\u003cbr\u003e\n\n---\n\n\u003e Emitte Spiritum tuum et creabuntur;\n\n\u003e Et renovabis faciem terrae.\n\n\u003e Send forth Thy Spirit and they shall be created\n\n\u003e And Thou shalt renew the face of the earth.\n\n[link](http://www1.cpdl.org/wiki/index.php/Emitte_spiritum_tuum)\n\nPsalm 104, \"Antiphon for Pentecost\"\n\n---\n\n\u003e The way to fame goes through the palaces,  \n\u003e the way to happiness goes through the markets,  \n\u003e the way to virtue goes through the deserts.  \n\nChinese proverb\n\n---\n\n\u003e Reading maketh a full man;\n\u003e conference a ready man;\n\u003e and writing an exact man;\n\u003e and, therefore, if a man write little, he had need have a great memory;\n\u003e if he confer little, he need have a present wit;\n\u003e and if he read little he need have much cunning to seem to know that he does not.\n\nFrancis Bacon\n\n---\n\n\u003e It may be, then, that form serves us best\nwhen it works as an obstruction to baffle us\nand deflect our intended course.\nIt may be that when we no longer know what to do\nwe have come to our real work and that\nwhen we no longer know which way to go\nwe have begun our real journey.\nThe mind that is not baffled is not employed.\nThe impeded stream is the one that sings.\n\nWendell Berry, \"Standing by Woods\"\n\n---\n\n\u003e It's dark because you are trying too hard.  \nLightly, child, lightly.  \nLearn to do everything lightly.  \n\nAldous Huxley\n\n---\n\n\u003e The most difficult things in the world  \nMust be accomplished through the easiest.  \nThe greatest things in the world  \nMust be accomplished through the smallest.  \nTherefore the Sage  \nNever attempts great things and so accomplishes them.  \n\nLao Tzu, _Tao Te Ching_ Chapter 63\n\n---\n\n\u003e The first and fundamental principle of our holy religion is,\nthat we believe that we have a right to embrace all,\nand every item of truth,\nwithout limitation or\nwithout being circumscribed or\nprohibited by the creeds or\nsuperstitious notions of men, or by the\ndominations of one another,\nwhen that truth is clearly demonstrated to our minds,\nand we have the highest degree of evidence of the same.\n\nJoseph Smith, Letter to Isaac Galland, Mar. 22, 1839, Liberty Jail\n\n---\n\n\u003esometimes it is necessary to shake the kaleidoscope: same elements - different pattern - new direction\n\nRoman Dale, personal communication, 4 June 2018\n\n---\n\n\u003eIf you observe a really happy man you will find him building a boat, writing a symphony, educating his son, or looking for dinosaur eggs in the Gobi Desert.\n\nW. Beran Wolfe, Australian psychiatrist\n\n\u003eFind a happy person, and you will find a project.\n\nSonja Lyubomirsky, psychologist\n\n---\n\n\u003eAs for the budget, a paper by Bjorken later put it this way: \n\u003e\"The location of the experiment in fiscal space was near the imaginary axis.\"\n\u003eFunding, in other words, was almost nonexistent.\n\n\u003chttps://artsci.case.edu/magazine/2020/an-unpredictable-trajectory/\u003e\n\nJ.D. Bjorken, theoretical physicist at Stanford\n\n---\n\n\u003eWe do not need a truth to serve us, \nwe need a truth that we can serve.\n\nJacques Maritain, *Degrees of Knowledge*, 1932\n\n---\n","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/notes/mistakes":{"title":"mistakes and systems","content":"\n# mistakes and systems\n\nLooking for systems that allowed for mistakes is a great idea,\nand [[Don Norman]] and [[Atul Gawande]] have done beautiful work\ndefining this generally (Norman) and for medicine (Gawande).\nBlame and fix systems, and allow people to thrive.\n\nWhat are the limits of system thinking?\nWhere is the boundary between personal responsibility and systemic responsibility?\nDoes the \"an explanation is not a justification\" idea dovetail into this?\n\nTue 30 Jun 2020 10:35:46 AM CDT\n","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/notes/oncology-alphabet-soup":{"title":"oncology alphabet soup","content":"\n# abbreviations\n\n- [[CTCAE]]: Common Terminology Criteria for Adverse Events [link](https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm)","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/notes/pdf-highlight-colors":{"title":"pdf highlight colors","content":"\n-   `red`--\u003edisagree with author\n-   `orange`--\u003eimportant point by author\n-   `yellow`--\u003einteresting point\n-   `green`--\u003eimportant to me\n-   `blue`--\u003enotes after initial iteration\n-   `magenta`--\u003eliterary note to look up later","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/notes/tomorrow_never_happens":{"title":"it's all the same fucking day, man","content":"\n\u003eI mean if you got a cat for one day, man  \nI mean, if you, say, say, if you want a cat for 365 days, right  \nyou ain't got him for 365 days, you got him for one day, man.  \nWell I tell you that one day, man, better be your life, man.  \nBecause, you know, you can say, oh man, you can cry about the other 364, man,  \nbut you're gonna lose that one day, man, and that's all you've got.  \nYou gotta call that love, man. That's what it is, man.  \nIf you got it today you don't want it tomorrow, man, 'cause you don't need it.  \n'Cause, as a matter of fact, as we discovered on the train,  \n**tomorrow never happens, man.  It's all the same fucking day, man.**  \n\n\n---\n\nJanis Joplin, \"Ball and Chain\"\n\n(Not really a lyric, more of a mid-song pontification).\n\nSun 17 Nov 2019 10:23:05 AM CST\n","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/reference/fassnachtAdrenocorticalCarcinomasMalignant2020":{"title":"Adrenocortical carcinomas and malignant phaeochromocytomas ESMOEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","content":"\n[btni:: incidence of paraganglioma and pheochromocytoma]\n[btn:: 2-8 million/year]\n\n[btni:: incidence of pants]\n[btn:: 8 million/year]\n","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null},"/reference/vermorkenWhereWhenUse2021":{"title":"Where and When to Use Induction Chemotherapy in Head and Neck Squamous Cell Cancer","content":"\n- [[HPV+ OPSCC incidence over time]]\n- \"...overall HPV prevalence in OPSCC is increasing significantly over time: \n- from 40.5% before 2000, \n\tto 64.3% between 2000 and 2004, \n\tand 72.2% between 2005 and 2009\"\n- \"age at OPSCC diagnosis is increasing for both HPV-positive and HPV-negative patients, and a rising proportion of older patients have HPV-positive tumors\"\n\n- [[OPSCC HPV+ survival ]]\n- overall, HPV+ OPSCC has better outcomes than HPV- OPSCC\n- age matters: HPV+ pts \u003e=70yo have similar survival to HPV- pts 50-59yo\n\n- [[HNSCC timeline of therapies]]\n- 1960s: MTX for recurrent or metastatic disease\n- 1970s, early: [[MTX]] vs [[cisplatin]] as part of a combined approach for stage IV, M1, recurrent w/o option for salvage\n\t- cisplatin single-agent RR 14-41% (higher if prev untx)\n- 1970s, late: cisplatin+[[bleomycin]], then added MTX or [[vinca_alkaloids]], then progressed to cisplatin+[[5-FU]]\n\t- 1977 Wayne State started a series of pilot studies, non-RCT:\n\t- prev untx, cisplatin+[[vincristine]]+bleomycin, RR 80%, CR 29%. \n\t- bc bleomycin had so much pulm tox and cis+5-FU ([[CF_PF]]) was the new hotness, follow-up study used CF (2 cycles, C 100mg/m2 D1, F 1000mg/m2/day x96h): RR 88%, CR 19%.\n\t- CF regimen then changed to run over 120h (another 1g of F) and 3 cycles: RR 93%, CR 38%\n\t- final CF regimen repeated by Radiation Therapy Oncology Group ([[RTOG]]): RR 86%, CR 38%.\n\t- next study tried to increase cisplatin, but no benefit was shown\n- 1980s (1979-1987): \n\t- 5x RCT w MTX, 4/5 -ve for survival\n\t\t- 1/5 +ve: gave [[intra-arterial]] MTX, benefit only present in stage II oral cavity cancer\n\t- other RCTs done, all -ve (again other than one study, a different one, that also used intra-arterial chemo and only showed benefit in oral cavity cancer)\n\t- noted that pts who responded well to chemo also responded well to RT\n- 1990s: [[CCRT]]\n\t- this paper uses CCRT to mean, specifically, \"Concurrent Cisplatin-based chemoRadiotherapy\"\n\t- CCRT used adjuvantly for unfavorable surgical results (R+, extracapsular extension), definitively for unresectable disease\n- 2000s: targeted therapy, IO, [[taxanes]]\n\t- two main RCTs, one in US and one in Europe, added [[docetaxel]] == [[TPF]]\n\t- TPF worked better than PF (see image below), more tolerable, cost-effective. \n\t- ~75% completed TPF+RT per protocol, ~25% had treatment delays during TPF\n\t- did not answer whether [[ICT]]+CCRT vs CCRT alone is better, and incidences of toxicities with ICT+CCRT is higher than with CCRT alone (febrile 11%, \"toxic death\" up to 6%)\n\t- European TPF ([[TAX323_EORTC24971]]): \n\t\t- 3 cycles\n\t\t- docetaxel 75mg/m2 x1\n\t\t- cisplatin 75mg/m2 x1\n\t\t- 5-FU 750mg/m2/day x5d (3750mg)\n\t\t- only prev untx, unresectable LA-HNSCC\n\t\t- RT afterward (4-7wks) if no disease progression, dealer's choice RT protocol (66-74 Gy in various fractionation schema)\n\t\t- Resection before or after RT, dealer's choice and clinical situation\n\t- American TPF ([[TAX324]]): \n\t\t- 4 cycles\n\t\t- docetaxel 75mg/m2 x1\n\t\t- cisplatin 100mg/m2 x1\n\t\t- 5-FU 1000mg/m2/day x4d (4000mg)\n\t\t- prev untx, unresectable/low likelihood of surgical cure, and pts who were candidates for organ preservation\n\t\t- CCRT afterward (3-8wks), 70-74Gy + carbo AUC 1.5 x7wks\n\t\t- resection 6-12wk s/p CCRT if resectable disease (e.g. not CR)\n\t\t- because of increased toxicities with TPF, modified regimens have been tried:\n\t\t\t- [[modified TPF]]: Fayette J, Fontaine-Delaruelle C, Ambrun A, et al. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF inlocally advanced head and neck squamous cell carcinoma: a study of 48 patients. Oncotarget. 2016;7:37297304.\n\t\t\t- [[weekly carbo+taxol]]: Herman LC, Chen L, Garnett A, et al. Comparison of carboplatin-paclitaxel to docetaxelcisplatin-5-fluorouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer. Oral Oncol. 2014;50:528.\n\t\t\t- [[TPEx]] (cisplatin, docetaxel, cetuximab): Zenda S, Ota Y, Kiyota N, etal. A multicenter phase II trial of docetaxel, cisplatin, and cetuximab (TPEx) followed by cetuximab and concurrent radiotherapy for patients with local advanced squamous cell carcinoma of the head and neck (CSPOR HN01: ECRIPS study). Front. Oncologia. 2019;9:6.\n\n\n\t![[files/TAX324_TAX323_20221209151920.png]]\n\n- [[ICT LA-HNSCC indications]]\n\t- larynx preservation\n\t\t\t- \n\t- treatment intensification (?)\n\t- borderline resectable or unresectable *oral cavity* cancer\n\t- selection tool for RT dose de-escalation in HPV+ OPSCC\n\t- oligometastatic disease\n\t","lastmodified":"2022-12-24T20:06:44.420611619Z","tags":null}}